https://trial.medpath.com/news/drug-farm-s-df-003-shows-promising-safety-profile-in-phase-1-trial-for-rare-rosah-syndrome 2025-05-29T15:58:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-farm-s-df-003-shows-promising-safety-profile-in-phase-1-trial-for-rare-rosah-syndrome 2025-05-29T15:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/estrella-immunopharma-advances-eb103-artemis-t-cell-therapy-to-second-cohort-in-starlight-1-trial-for-advanced-b-cell-lymphomas 2025-05-29T15:58:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/estrella-immunopharma-advances-eb103-artemis-t-cell-therapy-to-second-cohort-in-starlight-1-trial-for-advanced-b-cell-lymphomas 2025-05-29T15:58:03+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-daiichi-sankyo-withdraw-fda-application-for-lung-cancer-adc-after-survival-data-disappoints 2025-05-29T14:47:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-daiichi-sankyo-withdraw-fda-application-for-lung-cancer-adc-after-survival-data-disappoints 2025-05-29T14:47:08+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-secures-patent-for-dual-target-cancer-therapy-using-sirna-against-cd320-and-lrp2-receptors 2025-05-29T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaffinity-technologies-secures-patent-for-dual-target-cancer-therapy-using-sirna-against-cd320-and-lrp2-receptors 2025-05-29T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionical-emas-secures-exclusive-partnership-to-address-critical-european-fluorouracil-shortage 2025-05-29T14:01:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionical-emas-secures-exclusive-partnership-to-address-critical-european-fluorouracil-shortage 2025-05-29T14:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-submits-ind-application-for-novel-non-atropine-eye-drop-to-treat-pediatric-myopia 2025-05-29T14:00:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iveena-submits-ind-application-for-novel-non-atropine-eye-drop-to-treat-pediatric-myopia 2025-05-29T14:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-announces-ind-submission-to-the-u-s-fda-for-a-phase-2 2025-05-29T14:00:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iveena-announces-ind-submission-to-the-u-s-fda-for-a-phase-2 2025-05-29T14:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/kyzatrex-oral-testosterone-therapy-achieves-96-efficacy-rate-in-phase-3-trials-for-hypogonadism-treatment 2025-05-29T13:45:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyzatrex-oral-testosterone-therapy-achieves-96-efficacy-rate-in-phase-3-trials-for-hypogonadism-treatment 2025-05-29T13:45:16+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-faces-legal-challenges-as-study-links-depo-provera-to-increased-meningioma-risk 2025-05-29T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-faces-legal-challenges-as-study-links-depo-provera-to-increased-meningioma-risk 2025-05-29T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarvodaya-hospital-becomes-first-in-india-to-offer-terbium-161-psma-therapy-for-advanced-prostate-cancer 2025-05-29T12:39:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarvodaya-hospital-becomes-first-in-india-to-offer-terbium-161-psma-therapy-for-advanced-prostate-cancer 2025-05-29T12:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/excyte-doses-first-patient-with-yk012-world-s-first-t-cell-engager-for-primary-membranous-nephropathy 2025-05-29T12:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excyte-doses-first-patient-with-yk012-world-s-first-t-cell-engager-for-primary-membranous-nephropathy 2025-05-29T12:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-and-merck-withdraw-patritumab-deruxtecan-bla-after-phase-3-trial-fails-to-meet-overall-survival-endpoint 2025-05-29T12:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-and-merck-withdraw-patritumab-deruxtecan-bla-after-phase-3-trial-fails-to-meet-overall-survival-endpoint 2025-05-29T12:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/genor-biopharma-secures-nmpa-approval-for-lerociclib-cdk4-6-inhibitor-in-advanced-breast-cancer 2025-05-29T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genor-biopharma-secures-nmpa-approval-for-lerociclib-cdk4-6-inhibitor-in-advanced-breast-cancer 2025-05-29T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-mazdutide-achieves-breakthrough-as-world-s-first-gcg-glp-1-dual-receptor-agonist-for-weight-loss 2025-05-29T12:38:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-mazdutide-achieves-breakthrough-as-world-s-first-gcg-glp-1-dual-receptor-agonist-for-weight-loss 2025-05-29T12:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/court-rulings-shape-patent-safe-harbor-provision-s-impact-on-pharmaceutical-development 2025-05-29T08:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/court-rulings-shape-patent-safe-harbor-provision-s-impact-on-pharmaceutical-development 2025-05-29T08:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-presents-comprehensive-hematology-portfolio-data-at-eha-2025-congress 2025-05-29T05:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-presents-comprehensive-hematology-portfolio-data-at-eha-2025-congress 2025-05-29T05:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-clinical-trials-embrace-ai-and-digital-solutions-to-enhance-patient-centric-approaches 2025-05-29T04:46:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-clinical-trials-embrace-ai-and-digital-solutions-to-enhance-patient-centric-approaches 2025-05-29T04:46:04+00:00 hourly 0.9 https://trial.medpath.com/news/noxopharm-receives-ethics-approval-for-first-in-human-trial-of-sof-skn-in-cutaneous-lupus 2025-05-29T04:40:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noxopharm-receives-ethics-approval-for-first-in-human-trial-of-sof-skn-in-cutaneous-lupus 2025-05-29T04:40:13+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-initiates-phase-3-trial-of-picankibart-for-psoriasis-patients-with-inadequate-il-17-response 2025-05-29T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-initiates-phase-3-trial-of-picankibart-for-psoriasis-patients-with-inadequate-il-17-response 2025-05-29T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/implantable-biobattery-achieves-99-6-tumor-reduction-in-breakthrough-drug-free-cancer-treatment 2025-05-29T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implantable-biobattery-achieves-99-6-tumor-reduction-in-breakthrough-drug-free-cancer-treatment 2025-05-29T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/japan-launches-world-s-first-clinical-trials-for-artificial-blood-in-2025 2025-05-29T04:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-launches-world-s-first-clinical-trials-for-artificial-blood-in-2025 2025-05-29T04:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-lead-implementation-of-advanced-cell-and-gene-therapies-across-major-health-systems 2025-05-29T03:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-lead-implementation-of-advanced-cell-and-gene-therapies-across-major-health-systems 2025-05-29T03:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/iambic-therapeutics-showcases-ai-driven-drug-discovery-platform-at-multiple-investor-conferences 2025-05-29T02:42:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iambic-therapeutics-showcases-ai-driven-drug-discovery-platform-at-multiple-investor-conferences 2025-05-29T02:42:49+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-approaches-transform-bronchiectasis-management-as-research-centers-expand-nationwide 2025-05-29T02:42:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-approaches-transform-bronchiectasis-management-as-research-centers-expand-nationwide 2025-05-29T02:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-processed-foods-linked-to-increased-asthma-and-allergy-risk-in-children-research-shows 2025-05-29T02:42:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultra-processed-foods-linked-to-increased-asthma-and-allergy-risk-in-children-research-shows 2025-05-29T02:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/oral-ritlecitinib-combined-with-phototherapy-shows-enhanced-repigmentation-in-nonsegmental-vitiligo 2025-05-29T02:42:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-ritlecitinib-combined-with-phototherapy-shows-enhanced-repigmentation-in-nonsegmental-vitiligo 2025-05-29T02:42:38+00:00 hourly 0.9 https://trial.medpath.com/news/epivax-appoints-dr-vibha-jawa-as-chief-scientific-officer-to-lead-immunogenicity-strategy 2025-05-29T02:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epivax-appoints-dr-vibha-jawa-as-chief-scientific-officer-to-lead-immunogenicity-strategy 2025-05-29T02:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/first-line-treatment-options-for-metastatic-pancreatic 2025-05-29T02:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-line-treatment-options-for-metastatic-pancreatic 2025-05-29T02:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-links-covid-19-infection-and-adenoviral-vaccines-to-guillain-barre-syndrome-risk-clears-mrna-vaccines 2025-05-29T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-links-covid-19-infection-and-adenoviral-vaccines-to-guillain-barre-syndrome-risk-clears-mrna-vaccines 2025-05-29T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cancels-590-million-moderna-bird-flu-vaccine-contract-amid-mrna-technology-review 2025-05-29T00:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-cancels-590-million-moderna-bird-flu-vaccine-contract-amid-mrna-technology-review 2025-05-29T00:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-faces-generic-competition-as-third-parties-file-anda-challenges-for-adhd-drug-qelbree 2025-05-29T00:47:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supernus-faces-generic-competition-as-third-parties-file-anda-challenges-for-adhd-drug-qelbree 2025-05-29T00:47:44+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-and-merck-secure-patent-victory-blocking-lenvima-generic-until-2036 2025-05-29T00:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-and-merck-secure-patent-victory-blocking-lenvima-generic-until-2036 2025-05-29T00:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-menopause-drug-duavee-shows-promise-for-breast-cancer-prevention-in-phase-2-trial 2025-05-29T00:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-menopause-drug-duavee-shows-promise-for-breast-cancer-prevention-in-phase-2-trial 2025-05-29T00:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/ausperbio-secures-50-million-series-b-funding-to-advance-hepatitis-b-functional-cure-candidate-ahb-137 2025-05-29T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ausperbio-secures-50-million-series-b-funding-to-advance-hepatitis-b-functional-cure-candidate-ahb-137 2025-05-29T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-raises-695000-in-private-placement-to-fund-phase-ii-thio-101-cancer-trial 2025-05-29T00:46:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-raises-695000-in-private-placement-to-fund-phase-ii-thio-101-cancer-trial 2025-05-29T00:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/coremap-receives-fda-ide-approval-to-expand-novel-atrial-fibrillation-mapping-technology-study-to-u-s 2025-05-29T00:46:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coremap-receives-fda-ide-approval-to-expand-novel-atrial-fibrillation-mapping-technology-study-to-u-s 2025-05-29T00:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-receives-fda-approval-for-khindivi-first-hydrocortisone-oral-solution-for-pediatric-adrenal-insufficiency 2025-05-29T00:45:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-receives-fda-approval-for-khindivi-first-hydrocortisone-oral-solution-for-pediatric-adrenal-insufficiency 2025-05-29T00:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-in-class-trpm8-receptor-agonist-tryptyr-for-dry-eye-disease-treatment 2025-05-29T00:45:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-in-class-trpm8-receptor-agonist-tryptyr-for-dry-eye-disease-treatment 2025-05-29T00:45:51+00:00 hourly 0.9 https://trial.medpath.com/news/armored-anti-gpc3-jw-004-shows-increased-potency-against-hcc-bioworld 2025-05-29T00:45:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armored-anti-gpc3-jw-004-shows-increased-potency-against-hcc-bioworld 2025-05-29T00:45:35+00:00 hourly 0.9 https://trial.medpath.com/news/ira-biosimilar-incentives-drive-measurable-uptake-in-us-healthcare-facilities 2025-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ira-biosimilar-incentives-drive-measurable-uptake-in-us-healthcare-facilities 2025-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-and-chdi-foundation-extend-multi-decade 2025-05-28T22:45:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-and-chdi-foundation-extend-multi-decade 2025-05-28T22:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/cessatech-raises-dkk-14-8-million-to-accelerate-u-s-commercial-launch-of-pediatric-pain-treatment-ct001 2025-05-28T22:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cessatech-raises-dkk-14-8-million-to-accelerate-u-s-commercial-launch-of-pediatric-pain-treatment-ct001 2025-05-28T22:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/javara-secures-series-c-funding-to-expand-community-based-clinical-trial-access-into-oncology-and-cns 2025-05-28T21:46:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/javara-secures-series-c-funding-to-expand-community-based-clinical-trial-access-into-oncology-and-cns 2025-05-28T21:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/wacker-biotech-and-expression-manufacturing-form-strategic-partnership-to-accelerate-lentiviral-gene-therapy-development 2025-05-28T21:45:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wacker-biotech-and-expression-manufacturing-form-strategic-partnership-to-accelerate-lentiviral-gene-therapy-development 2025-05-28T21:45:47+00:00 hourly 0.9 https://trial.medpath.com/news/canada-launches-first-home-based-cancer-immunotherapy-trial-using-subcutaneous-injection 2025-05-28T20:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-launches-first-home-based-cancer-immunotherapy-trial-using-subcutaneous-injection 2025-05-28T20:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-plasma-exchange-combined-with-immunoglobulin-reduces-biological-age-by-2-6-years-in-clinical-trial 2025-05-28T20:49:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-plasma-exchange-combined-with-immunoglobulin-reduces-biological-age-by-2-6-years-in-clinical-trial 2025-05-28T20:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-achieve-first-ever-production-of-human-dnase1-in-yeast-offering-cost-effective-alternative-to-hamster-cell-manufacturing 2025-05-28T20:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-achieve-first-ever-production-of-human-dnase1-in-yeast-offering-cost-effective-alternative-to-hamster-cell-manufacturing 2025-05-28T20:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/texas-approves-50-million-for-ibogaine-research-initiative-largest-state-funded-psychedelic-program-in-us-history 2025-05-28T20:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-approves-50-million-for-ibogaine-research-initiative-largest-state-funded-psychedelic-program-in-us-history 2025-05-28T20:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-announces-appointment-of-dr-christopher-wright-as-chief-medical-officer 2025-05-28T20:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-announces-appointment-of-dr-christopher-wright-as-chief-medical-officer 2025-05-28T20:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-radiation-therapy-shows-superior-quality-of-life-benefits-over-hippocampal-avoidance-wbrt-in-brain-metastases-trial 2025-05-28T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotactic-radiation-therapy-shows-superior-quality-of-life-benefits-over-hippocampal-avoidance-wbrt-in-brain-metastases-trial 2025-05-28T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hyperfine-receives-fda-clearance-for-ai-enhanced-portable-mri-software-approaching-conventional-scanner-quality 2025-05-28T19:44:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyperfine-receives-fda-clearance-for-ai-enhanced-portable-mri-software-approaching-conventional-scanner-quality 2025-05-28T19:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/enthera-pharmaceuticals-announces-publication-in-the-journal-of-clinical-investigation-supporting-the-clinical-development-of-ebrasodebart 2025-05-28T18:47:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enthera-pharmaceuticals-announces-publication-in-the-journal-of-clinical-investigation-supporting-the-clinical-development-of-ebrasodebart 2025-05-28T18:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-discover-critical-window-for-in-vivo-gene-therapy-in-newborns 2025-05-28T18:46:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-discover-critical-window-for-in-vivo-gene-therapy-in-newborns 2025-05-28T18:46:58+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-acquires-30-million-mezagitamab-rights-from-bioinvent-as-anti-cd38-antibody-advances-to-phase-3 2025-05-28T18:46:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-acquires-30-million-mezagitamab-rights-from-bioinvent-as-anti-cd38-antibody-advances-to-phase-3 2025-05-28T18:46:27+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-s-holdipharma-forms-strategic-joint-venture-with-us-partner-to-enter-north-american-and-european-markets 2025-05-28T18:45:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-s-holdipharma-forms-strategic-joint-venture-with-us-partner-to-enter-north-american-and-european-markets 2025-05-28T18:45:40+00:00 hourly 0.9 https://trial.medpath.com/news/bora-pharmaceuticals-expands-sterile-fill-finish-capacity-in-baltimore-to-meet-growing-demand-for-high-value-drug-products 2025-05-28T17:55:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bora-pharmaceuticals-expands-sterile-fill-finish-capacity-in-baltimore-to-meet-growing-demand-for-high-value-drug-products 2025-05-28T17:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-discontinues-acurate-tavr-program-after-clinical-trial-failure 2025-05-28T17:53:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-discontinues-acurate-tavr-program-after-clinical-trial-failure 2025-05-28T17:53:56+00:00 hourly 0.9 https://trial.medpath.com/news/proteinqure-secures-11m-series-a-to-advance-first-ai-designed-peptide-therapeutic-for-triple-negative-breast-cancer 2025-05-28T17:53:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteinqure-secures-11m-series-a-to-advance-first-ai-designed-peptide-therapeutic-for-triple-negative-breast-cancer 2025-05-28T17:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-drug-combination-extends-mouse-lifespan-by-30-in-aging-research-breakthrough 2025-05-28T17:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-drug-combination-extends-mouse-lifespan-by-30-in-aging-research-breakthrough 2025-05-28T17:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/aphios-receives-u-s-patent-allowance-for-room-temperature-stable-single-shot-mrna-covid-19-vaccine 2025-05-28T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aphios-receives-u-s-patent-allowance-for-room-temperature-stable-single-shot-mrna-covid-19-vaccine 2025-05-28T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-clinical-decision-support-system-accelerates-bacteremia-treatment-by-29-hours-in-groundbreaking-study 2025-05-28T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-clinical-decision-support-system-accelerates-bacteremia-treatment-by-29-hours-in-groundbreaking-study 2025-05-28T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/carb-x-awards-debiopharm-additional-12-3-million-to-advance-novel-antibiotic-debio-1453-against-drug-resistant-gonorrhea 2025-05-28T16:51:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carb-x-awards-debiopharm-additional-12-3-million-to-advance-novel-antibiotic-debio-1453-against-drug-resistant-gonorrhea 2025-05-28T16:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/monarch-therapeutics-and-snap-biosciences-partner-to-advance-car-nk-cell-therapy-with-small-molecule-adaptor-technology 2025-05-28T16:50:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monarch-therapeutics-and-snap-biosciences-partner-to-advance-car-nk-cell-therapy-with-small-molecule-adaptor-technology 2025-05-28T16:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/hillstar-bio-strengthens-leadership-team-with-key-appointments-to-advance-precision-immunotherapy-pipeline 2025-05-28T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillstar-bio-strengthens-leadership-team-with-key-appointments-to-advance-precision-immunotherapy-pipeline 2025-05-28T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aligns-with-olema-on-90mg-palazestrant-dose-for-phase-3-breast-cancer-trials 2025-05-28T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aligns-with-olema-on-90mg-palazestrant-dose-for-phase-3-breast-cancer-trials 2025-05-28T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/octapharma-s-panzyga-shows-mixed-results-in-phase-3-pans-trial-achieves-significant-secondary-endpoint 2025-05-28T16:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/octapharma-s-panzyga-shows-mixed-results-in-phase-3-pans-trial-achieves-significant-secondary-endpoint 2025-05-28T16:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/archeus-technologies-and-warf-partner-to-advance-novel-prostate-cancer-radiopharmaceutical-art-101-into-phase-1-trials 2025-05-28T16:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archeus-technologies-and-warf-partner-to-advance-novel-prostate-cancer-radiopharmaceutical-art-101-into-phase-1-trials 2025-05-28T16:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/veru-s-enobosarm-shows-improved-safety-profile-in-combination-with-wegovy-for-muscle-preserving-obesity-treatment 2025-05-28T16:49:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veru-s-enobosarm-shows-improved-safety-profile-in-combination-with-wegovy-for-muscle-preserving-obesity-treatment 2025-05-28T16:49:21+00:00 hourly 0.9 https://trial.medpath.com/news/tpn-101-selected-for-healey-als-platform-trial-following-promising-phase-2-results-in-c9orf72-related-als 2025-05-28T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tpn-101-selected-for-healey-als-platform-trial-following-promising-phase-2-results-in-c9orf72-related-als 2025-05-28T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-phase-1b-trial-for-novel-nectin-4-targeted-radiopharmaceutical-aky-1189-across-multiple-cancer-types 2025-05-28T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-phase-1b-trial-for-novel-nectin-4-targeted-radiopharmaceutical-aky-1189-across-multiple-cancer-types 2025-05-28T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/lumanity-and-parker-institute-form-strategic-alliance-to-accelerate-cancer-immunotherapy-development 2025-05-28T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumanity-and-parker-institute-form-strategic-alliance-to-accelerate-cancer-immunotherapy-development 2025-05-28T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-advances-sirt6-gene-therapy-pipeline-with-strategic-partnerships-and-patent-expansion 2025-05-28T16:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-advances-sirt6-gene-therapy-pipeline-with-strategic-partnerships-and-patent-expansion 2025-05-28T16:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-eliminates-347-million-share-dilution-ahead-of-pivotal-sleep-apnea-drug-trial-results 2025-05-28T16:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incannex-eliminates-347-million-share-dilution-ahead-of-pivotal-sleep-apnea-drug-trial-results 2025-05-28T16:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-eb-003-shows-statistically-significant-antidepressant-effects-in-preclinical-depression-model 2025-05-28T16:46:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-eb-003-shows-statistically-significant-antidepressant-effects-in-preclinical-depression-model 2025-05-28T16:46:56+00:00 hourly 0.9 https://trial.medpath.com/news/collplant-advances-regenerative-breast-implant-technology-with-promising-preclinical-results 2025-05-28T16:46:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collplant-advances-regenerative-breast-implant-technology-with-promising-preclinical-results 2025-05-28T16:46:25+00:00 hourly 0.9 https://trial.medpath.com/news/tq-therapeutics-acquires-juno-gmbh-to-advance-decentralized-cell-therapy-platform 2025-05-28T16:46:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tq-therapeutics-acquires-juno-gmbh-to-advance-decentralized-cell-therapy-platform 2025-05-28T16:46:23+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-s-ai-discovered-anti-inflammatory-env-294-clears-phase-1-safety-trial-advances-to-atopic-dermatitis-study 2025-05-28T16:46:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveda-s-ai-discovered-anti-inflammatory-env-294-clears-phase-1-safety-trial-advances-to-atopic-dermatitis-study 2025-05-28T16:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-novel-adcs-show-promising-early-clinical-results-with-topoix-payload-technology 2025-05-28T16:21:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-novel-adcs-show-promising-early-clinical-results-with-topoix-payload-technology 2025-05-28T16:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/debra-research-and-dermaliq-partner-to-develop-touchless-drug-delivery-for-epidermolysis-bullosa 2025-05-28T16:21:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debra-research-and-dermaliq-partner-to-develop-touchless-drug-delivery-for-epidermolysis-bullosa 2025-05-28T16:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-receives-patent-allowances-for-novel-fenestrated-placental-allografts 2025-05-28T16:20:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostem-technologies-receives-patent-allowances-for-novel-fenestrated-placental-allografts 2025-05-28T16:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-partners-with-telesis-bio-to-deploy-revolutionary-dna-synthesis-platform-for-accelerated-drug-development 2025-05-28T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-partners-with-telesis-bio-to-deploy-revolutionary-dna-synthesis-platform-for-accelerated-drug-development 2025-05-28T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/radyus-research-and-eurofins-cdmo-alphora-form-strategic-partnership-to-accelerate-early-stage-drug-development 2025-05-28T16:19:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radyus-research-and-eurofins-cdmo-alphora-form-strategic-partnership-to-accelerate-early-stage-drug-development 2025-05-28T16:19:58+00:00 hourly 0.9 https://trial.medpath.com/news/nuclera-and-cytiva-partnership-reduces-protein-characterization-timeline-from-months-to-five-days 2025-05-28T16:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclera-and-cytiva-partnership-reduces-protein-characterization-timeline-from-months-to-five-days 2025-05-28T16:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/redeye-synact-pharma-q1-2025-new-phase-ii-study-in-dengue-fever-tradingview 2025-05-28T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redeye-synact-pharma-q1-2025-new-phase-ii-study-in-dengue-fever-tradingview 2025-05-28T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/distalmotion-receives-fda-510-k-clearance-for-dexter-robotic-surgery-system-in-cholecystectomy 2025-05-28T16:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/distalmotion-receives-fda-510-k-clearance-for-dexter-robotic-surgery-system-in-cholecystectomy 2025-05-28T16:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-and-advanz-pharma-expand-13-8-billion-biosimilar-partnership-with-three-new-candidates 2025-05-28T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-and-advanz-pharma-expand-13-8-billion-biosimilar-partnership-with-three-new-candidates 2025-05-28T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-holdings-inc-provides-development-update-on-buzz-bomb-tm-usa-today 2025-05-28T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-biopharma-holdings-inc-provides-development-update-on-buzz-bomb-tm-usa-today 2025-05-28T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-infiltrating-lymphocytes-emerge-as-key-biomarkers-for-nsclc-immunotherapy-response 2025-05-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-infiltrating-lymphocytes-emerge-as-key-biomarkers-for-nsclc-immunotherapy-response 2025-05-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-developed-pill-could-ease-distressing-behaviours-in 2025-05-28T15:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-developed-pill-could-ease-distressing-behaviours-in 2025-05-28T15:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-tebipenem-hbr-phase-iii-trial-stopped-early-for-efficacy-in-complicated-uti-treatment 2025-05-28T15:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-tebipenem-hbr-phase-iii-trial-stopped-early-for-efficacy-in-complicated-uti-treatment 2025-05-28T15:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/german-radiopharmaceutical-biotech-itm-secures-262-5m-debt-financing-to-advance-cancer-treatment-technologies 2025-05-28T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-radiopharmaceutical-biotech-itm-secures-262-5m-debt-financing-to-advance-cancer-treatment-technologies 2025-05-28T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/medable-launches-digital-platform-to-address-20-dropout-rate-in-cell-and-gene-therapy-long-term-follow-up-studies 2025-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medable-launches-digital-platform-to-address-20-dropout-rate-in-cell-and-gene-therapy-long-term-follow-up-studies 2025-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-evaluates-host-directed-therapies-for-rifampicin-resistant-tuberculosis 2025-05-28T12:41:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-evaluates-host-directed-therapies-for-rifampicin-resistant-tuberculosis 2025-05-28T12:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/pimicotinib-achieves-54-response-rate-in-phase-3-trial-for-rare-joint-tumor 2025-05-28T12:40:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pimicotinib-achieves-54-response-rate-in-phase-3-trial-for-rare-joint-tumor 2025-05-28T12:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-reports-promising-phase-1-data-for-novel-mrna-cancer-therapy-stx-001 2025-05-28T12:40:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-reports-promising-phase-1-data-for-novel-mrna-cancer-therapy-stx-001 2025-05-28T12:40:45+00:00 hourly 0.9 https://trial.medpath.com/news/st-george-s-hospital-achieves-majority-remission-rate-in-first-car-t-cell-therapy-patients 2025-05-28T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-george-s-hospital-achieves-majority-remission-rate-in-first-car-t-cell-therapy-patients 2025-05-28T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/alamar-biosciences-partners-with-scilifelab-to-advance-precision-proteomics-for-early-disease-detection 2025-05-28T12:40:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alamar-biosciences-partners-with-scilifelab-to-advance-precision-proteomics-for-early-disease-detection 2025-05-28T12:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/ttf-1-biomarker-predicts-survival-outcomes-for-kras-inhibitor-sotorasib-in-lung-cancer 2025-05-28T12:40:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ttf-1-biomarker-predicts-survival-outcomes-for-kras-inhibitor-sotorasib-in-lung-cancer 2025-05-28T12:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-launches-7-tender-offer-for-regulus-therapeutics-with-additional-regulatory-milestone-payment 2025-05-28T12:39:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-launches-7-tender-offer-for-regulus-therapeutics-with-additional-regulatory-milestone-payment 2025-05-28T12:39:19+00:00 hourly 0.9 https://trial.medpath.com/news/arcticzymes-and-austrian-centre-extend-partnership-to-advance-bionanoparticle-purification-for-gene-therapies 2025-05-28T12:38:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcticzymes-and-austrian-centre-extend-partnership-to-advance-bionanoparticle-purification-for-gene-therapies 2025-05-28T12:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/british-columbia-biosimilar-policy-shows-no-impact-on-healthcare-utilization-for-inflammatory-arthritis-patients 2025-05-28T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/british-columbia-biosimilar-policy-shows-no-impact-on-healthcare-utilization-for-inflammatory-arthritis-patients 2025-05-28T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-to-present-clinical-data-on-rare-disease-therapies-at-eular-2025 2025-05-28T12:37:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-to-present-clinical-data-on-rare-disease-therapies-at-eular-2025 2025-05-28T12:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/efficacy-and-safety-of-a-house-dust-mites-allergoid-in-patients-with-allergic-rhinitis 2025-05-28T12:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efficacy-and-safety-of-a-house-dust-mites-allergoid-in-patients-with-allergic-rhinitis 2025-05-28T12:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/bd-launches-xtract-registry-to-evaluate-real-world-outcomes-of-rotarex-atherectomy-system-in-peripheral-artery-disease 2025-05-28T12:37:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-launches-xtract-registry-to-evaluate-real-world-outcomes-of-rotarex-atherectomy-system-in-peripheral-artery-disease 2025-05-28T12:37:49+00:00 hourly 0.9 https://trial.medpath.com/news/french-biotech-kyron-bio-raises-eur5-5m-to-advance-glycan-controlled-antibody-therapeutics 2025-05-28T08:44:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/french-biotech-kyron-bio-raises-eur5-5m-to-advance-glycan-controlled-antibody-therapeutics 2025-05-28T08:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/blinatumomab-combination-therapy-wins-prestigious-trial-of-the-year-award-for-pediatric-leukemia-breakthrough 2025-05-28T08:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinatumomab-combination-therapy-wins-prestigious-trial-of-the-year-award-for-pediatric-leukemia-breakthrough 2025-05-28T08:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-s-ebc-129-antibody-drug-conjugate-receives-fda-fast-track-designation-for-pancreatic-cancer-treatment 2025-05-28T08:15:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-s-ebc-129-antibody-drug-conjugate-receives-fda-fast-track-designation-for-pancreatic-cancer-treatment 2025-05-28T08:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/portal-access-secures-7m-series-a-to-advance-next-generation-chemotherapy-port-through-fda-approval 2025-05-28T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portal-access-secures-7m-series-a-to-advance-next-generation-chemotherapy-port-through-fda-approval 2025-05-28T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-partners-with-city-therapeutics-to-develop-rnai-therapies-for-central-nervous-system-diseases 2025-05-28T04:58:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-partners-with-city-therapeutics-to-develop-rnai-therapies-for-central-nervous-system-diseases 2025-05-28T04:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-intellectual-property-high-court-orders-y-21-7-billion-patent-infringement-payout-for-toray-s-anti-itch-drug 2025-05-28T04:43:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-intellectual-property-high-court-orders-y-21-7-billion-patent-infringement-payout-for-toray-s-anti-itch-drug 2025-05-28T04:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/olympus-receives-fda-clearance-for-advanced-edof-endoscopy-technology-to-enhance-gi-lesion-detection 2025-05-28T04:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olympus-receives-fda-clearance-for-advanced-edof-endoscopy-technology-to-enhance-gi-lesion-detection 2025-05-28T04:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-ai-platform-cuts-clinical-audit-time-by-90-partners-with-roche-for-clinical-trial-acceleration 2025-05-28T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-ai-platform-cuts-clinical-audit-time-by-90-partners-with-roche-for-clinical-trial-acceleration 2025-05-28T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/oncologists-address-diagnostic-challenges-and-treatment-advances-in-nasopharyngeal-cancer 2025-05-28T03:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncologists-address-diagnostic-challenges-and-treatment-advances-in-nasopharyngeal-cancer 2025-05-28T03:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-advances-lyme-disease-vaccine-vla15-with-pfizer-partnership-as-phase-3-data-expected-by-end-of-2025 2025-05-28T03:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-advances-lyme-disease-vaccine-vla15-with-pfizer-partnership-as-phase-3-data-expected-by-end-of-2025 2025-05-28T03:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/community-oncology-practices-expand-access-to-car-t-and-bispecific-therapies-as-workforce-challenges-persist 2025-05-28T02:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-oncology-practices-expand-access-to-car-t-and-bispecific-therapies-as-workforce-challenges-persist 2025-05-28T02:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-appoints-bristol-myers-squibb-veteran-to-lead-rare-disease-commercial-strategy 2025-05-28T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-appoints-bristol-myers-squibb-veteran-to-lead-rare-disease-commercial-strategy 2025-05-28T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/salvia-raises-60m-for-neuromodulation-migraine-system 2025-05-28T01:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salvia-raises-60m-for-neuromodulation-migraine-system 2025-05-28T01:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-sequoia-data-confirms-zanubrutinib-s-long-term-efficacy-in-high-risk-cll-sll-patients 2025-05-28T00:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-sequoia-data-confirms-zanubrutinib-s-long-term-efficacy-in-high-risk-cll-sll-patients 2025-05-28T00:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-advances-imetelstat-as-potential-game-changer-for-jak-inhibitor-resistant-myelofibrosis 2025-05-28T00:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-advances-imetelstat-as-potential-game-changer-for-jak-inhibitor-resistant-myelofibrosis 2025-05-28T00:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-teva-s-tev-53408-for-celiac-disease-treatment 2025-05-28T00:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-teva-s-tev-53408-for-celiac-disease-treatment 2025-05-28T00:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-solutions-transform-pharmaceutical-supply-chain-management-amid-growing-disruptions 2025-05-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-solutions-transform-pharmaceutical-supply-chain-management-amid-growing-disruptions 2025-05-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-develop-in-vivo-car-t-cell-engineering-to-reduce-cancer-treatment-costs-and-complexity 2025-05-27T23:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-develop-in-vivo-car-t-cell-engineering-to-reduce-cancer-treatment-costs-and-complexity 2025-05-27T23:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/seres-therapeutics-ser-155-shows-promise-for-immune-recovery-in-stem-cell-transplant-patients 2025-05-27T20:57:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seres-therapeutics-ser-155-shows-promise-for-immune-recovery-in-stem-cell-transplant-patients 2025-05-27T20:57:33+00:00 hourly 0.9 https://trial.medpath.com/news/hibercell-completes-dose-escalation-phase-for-hc-7366-plus-belzutifan-in-advanced-kidney-cancer-trial 2025-05-27T20:38:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hibercell-completes-dose-escalation-phase-for-hc-7366-plus-belzutifan-in-advanced-kidney-cancer-trial 2025-05-27T20:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/vancouver-general-hospital-launches-canada-s-first-dedicated-inpatient-clinical-trials-unit-for-blood-cancer-therapies 2025-05-27T20:38:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vancouver-general-hospital-launches-canada-s-first-dedicated-inpatient-clinical-trials-unit-for-blood-cancer-therapies 2025-05-27T20:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/bcli-receives-regulatory-clearance-to-initiate-phase-3b-als-trial-smartkarma 2025-05-27T20:38:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcli-receives-regulatory-clearance-to-initiate-phase-3b-als-trial-smartkarma 2025-05-27T20:38:03+00:00 hourly 0.9 https://trial.medpath.com/news/ovarian-cancer-survival-disparities-revealed-among-asian-american-subgroups-despite-overall-lower-mortality-rates 2025-05-27T20:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovarian-cancer-survival-disparities-revealed-among-asian-american-subgroups-despite-overall-lower-mortality-rates 2025-05-27T20:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/celecor-completes-phase-3-trial-of-novel-pre-hospital-heart-attack-drug-disaggpro 2025-05-27T20:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celecor-completes-phase-3-trial-of-novel-pre-hospital-heart-attack-drug-disaggpro 2025-05-27T20:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/saga-diagnostics-launches-pathlight-mrd-test-with-100-sensitivity-for-early-breast-cancer-detection 2025-05-27T20:17:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saga-diagnostics-launches-pathlight-mrd-test-with-100-sensitivity-for-early-breast-cancer-detection 2025-05-27T20:17:30+00:00 hourly 0.9 https://trial.medpath.com/news/neuralink-secures-600m-funding-round-valuation-soars-to-9b-following-fda-breakthrough-designation 2025-05-27T20:17:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuralink-secures-600m-funding-round-valuation-soars-to-9b-following-fda-breakthrough-designation 2025-05-27T20:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/guided-therapeutics-secures-700000-order-for-luviva-cervical-cancer-screening-systems-in-china 2025-05-27T20:17:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guided-therapeutics-secures-700000-order-for-luviva-cervical-cancer-screening-systems-in-china 2025-05-27T20:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/anx-robotica-receives-fda-510-k-clearance-for-motilicap-and-motiliscan-gi-motility-monitoring-system 2025-05-27T20:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anx-robotica-receives-fda-510-k-clearance-for-motilicap-and-motiliscan-gi-motility-monitoring-system 2025-05-27T20:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/pearl-achieves-historic-fda-clearance-for-first-ai-platform-supporting-both-2d-and-3d-dental-imaging-analysis 2025-05-27T20:16:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pearl-achieves-historic-fda-clearance-for-first-ai-platform-supporting-both-2d-and-3d-dental-imaging-analysis 2025-05-27T20:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/imlifidase-shows-rapid-functional-recovery-in-phase-2-guillain-barre-syndrome-trial 2025-05-27T19:45:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imlifidase-shows-rapid-functional-recovery-in-phase-2-guillain-barre-syndrome-trial 2025-05-27T19:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/drug-farm-and-amoytop-partner-on-first-in-class-alpk1-agonist-df-006-for-hepatitis-b-and-liver-cancer-treatment 2025-05-27T18:44:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-farm-and-amoytop-partner-on-first-in-class-alpk1-agonist-df-006-for-hepatitis-b-and-liver-cancer-treatment 2025-05-27T18:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-drug-lamivudine-shows-promise-as-oral-treatment-for-diabetic-macular-edema-in-clinical-trial 2025-05-27T17:01:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-drug-lamivudine-shows-promise-as-oral-treatment-for-diabetic-macular-edema-in-clinical-trial 2025-05-27T17:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-partners-with-undisclosed-company-to-advance-circular-rna-delivery-platform 2025-05-27T17:00:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altamira-therapeutics-partners-with-undisclosed-company-to-advance-circular-rna-delivery-platform 2025-05-27T17:00:51+00:00 hourly 0.9 https://trial.medpath.com/news/brooklyn-health-raises-6-5m-to-transform-cns-clinical-trial-measurement-with-ai-powered-platform 2025-05-27T17:00:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brooklyn-health-raises-6-5m-to-transform-cns-clinical-trial-measurement-with-ai-powered-platform 2025-05-27T17:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-partners-with-saudi-arabia-to-bring-fda-approved-cancer-bioshield-platform-to-middle-east 2025-05-27T16:58:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-partners-with-saudi-arabia-to-bring-fda-approved-cancer-bioshield-platform-to-middle-east 2025-05-27T16:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/vgenomics-partners-with-dr-shroff-s-eye-hospital-to-validate-ai-powered-tear-biomarker-for-early-keratoconus-detection 2025-05-27T16:57:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vgenomics-partners-with-dr-shroff-s-eye-hospital-to-validate-ai-powered-tear-biomarker-for-early-keratoconus-detection 2025-05-27T16:57:27+00:00 hourly 0.9 https://trial.medpath.com/news/salvia-bioelectronics-raises-60m-series-b-to-advance-breakthrough-neuromodulation-therapy-for-chronic-migraine 2025-05-27T16:56:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salvia-bioelectronics-raises-60m-series-b-to-advance-breakthrough-neuromodulation-therapy-for-chronic-migraine 2025-05-27T16:56:04+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-secures-80m-financing-to-advance-genetic-heart-disease-therapies 2025-05-27T16:56:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexeo-therapeutics-secures-80m-financing-to-advance-genetic-heart-disease-therapies 2025-05-27T16:56:02+00:00 hourly 0.9 https://trial.medpath.com/news/storm-therapeutics-initiates-first-in-class-rna-modification-therapy-combination-trial-with-checkpoint-inhibitor 2025-05-27T16:55:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/storm-therapeutics-initiates-first-in-class-rna-modification-therapy-combination-trial-with-checkpoint-inhibitor 2025-05-27T16:55:57+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-expands-strategic-partnership-with-shanghai-pharma-to-accelerate-ophthalmic-drug-distribution-in-china 2025-05-27T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-expands-strategic-partnership-with-shanghai-pharma-to-accelerate-ophthalmic-drug-distribution-in-china 2025-05-27T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-courts-block-msn-laboratories-early-launch-of-generic-entresto-until-july-2025 2025-05-27T16:54:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-courts-block-msn-laboratories-early-launch-of-generic-entresto-until-july-2025 2025-05-27T16:54:56+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-siteone-therapeutics-for-up-to-1-billion-to-advance-non-opioid-pain-treatment 2025-05-27T16:54:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-acquires-siteone-therapeutics-for-up-to-1-billion-to-advance-non-opioid-pain-treatment 2025-05-27T16:54:31+00:00 hourly 0.9 https://trial.medpath.com/news/bioivt-and-handok-biotech-form-exclusive-partnership-to-expand-biospecimen-access-in-south-korea 2025-05-27T16:54:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioivt-and-handok-biotech-form-exclusive-partnership-to-expand-biospecimen-access-in-south-korea 2025-05-27T16:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/non-invasive-ear-stimulation-shows-promise-for-osteoarthritis-knee-pain-relief 2025-05-27T16:53:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-invasive-ear-stimulation-shows-promise-for-osteoarthritis-knee-pain-relief 2025-05-27T16:53:07+00:00 hourly 0.9 https://trial.medpath.com/news/john-snow-labs-acquires-wisecube-to-enhance-medical-ai-with-billion-scale-knowledge-graphs 2025-05-27T16:53:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/john-snow-labs-acquires-wisecube-to-enhance-medical-ai-with-billion-scale-knowledge-graphs 2025-05-27T16:53:05+00:00 hourly 0.9 https://trial.medpath.com/news/iolyx-therapeutics-reports-positive-phase-2-results-for-ilyx-002-in-autoimmune-associated-dry-eye-disease 2025-05-27T16:53:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iolyx-therapeutics-reports-positive-phase-2-results-for-ilyx-002-in-autoimmune-associated-dry-eye-disease 2025-05-27T16:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/maxiom-launches-ai-powered-health-coach-platform-enters-clinical-trials-to-validate-performance-against-human-experts 2025-05-27T16:52:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxiom-launches-ai-powered-health-coach-platform-enters-clinical-trials-to-validate-performance-against-human-experts 2025-05-27T16:52:19+00:00 hourly 0.9 https://trial.medpath.com/news/pillar-biosciences-secures-34-5m-funding-round-led-by-illumina-to-advance-ngs-cancer-testing-platform 2025-05-27T16:52:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pillar-biosciences-secures-34-5m-funding-round-led-by-illumina-to-advance-ngs-cancer-testing-platform 2025-05-27T16:52:17+00:00 hourly 0.9 https://trial.medpath.com/news/neuropace-s-rns-system-shows-promise-in-idiopathic-generalized-epilepsy-trial-despite-mixed-primary-endpoint-results 2025-05-27T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuropace-s-rns-system-shows-promise-in-idiopathic-generalized-epilepsy-trial-despite-mixed-primary-endpoint-results 2025-05-27T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/grin-therapeutics-secures-140m-series-d-and-global-partnership-with-angelini-pharma-for-radiprodil-development 2025-05-27T16:52:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grin-therapeutics-secures-140m-series-d-and-global-partnership-with-angelini-pharma-for-radiprodil-development 2025-05-27T16:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/syndeio-biosciences-launches-with-90m-to-target-synaptic-dysfunction-in-alzheimer-s-and-depression 2025-05-27T16:51:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syndeio-biosciences-launches-with-90m-to-target-synaptic-dysfunction-in-alzheimer-s-and-depression 2025-05-27T16:51:59+00:00 hourly 0.9 https://trial.medpath.com/news/curifylabs-secures-eur6-7m-to-automate-personalized-medicine-manufacturing-with-ai-driven-platform 2025-05-27T16:51:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curifylabs-secures-eur6-7m-to-automate-personalized-medicine-manufacturing-with-ai-driven-platform 2025-05-27T16:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/palvella-therapeutics-appoints-rare-disease-commercial-expert-ashley-kline-as-chief-commercial-officer 2025-05-27T16:50:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palvella-therapeutics-appoints-rare-disease-commercial-expert-ashley-kline-as-chief-commercial-officer 2025-05-27T16:50:43+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-tendyne-system-receives-fda-approval-as-first-transcatheter-mitral-valve-replacement-for-severe-calcification 2025-05-27T16:50:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-tendyne-system-receives-fda-approval-as-first-transcatheter-mitral-valve-replacement-for-severe-calcification 2025-05-27T16:50:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-menquadfi-meningococcal-vaccine-approval-to-include-infants-as-young-as-6-weeks 2025-05-27T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-menquadfi-meningococcal-vaccine-approval-to-include-infants-as-young-as-6-weeks 2025-05-27T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-biolojic-design-launch-ind-enabling-studies-for-dual-target-bd9-antibody-in-inflammatory-diseases 2025-05-27T16:50:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-and-biolojic-design-launch-ind-enabling-studies-for-dual-target-bd9-antibody-in-inflammatory-diseases 2025-05-27T16:50:08+00:00 hourly 0.9 https://trial.medpath.com/news/eu-to-track-decentralized-clinical-trials-in-ctis-to-support-innovation-pink-sheet 2025-05-27T16:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-to-track-decentralized-clinical-trials-in-ctis-to-support-innovation-pink-sheet 2025-05-27T16:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-partners-with-city-therapeutics-in-1-billion-rnai-collaboration-for-cns-diseases 2025-05-27T15:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-partners-with-city-therapeutics-in-1-billion-rnai-collaboration-for-cns-diseases 2025-05-27T15:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-launches-first-clozapine-orally-disintegrating-tablet-in-canada-for-treatment-resistant-schizophrenia 2025-05-27T15:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-launches-first-clozapine-orally-disintegrating-tablet-in-canada-for-treatment-resistant-schizophrenia 2025-05-27T15:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/apotex-launches-first-generic-nilotinib-in-us-with-180-day-market-exclusivity 2025-05-27T15:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apotex-launches-first-generic-nilotinib-in-us-with-180-day-market-exclusivity 2025-05-27T15:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/pyc-therapeutics-advances-pyc-003-to-second-cohort-in-phase-ia-trial-for-polycystic-kidney-disease 2025-05-27T15:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyc-therapeutics-advances-pyc-003-to-second-cohort-in-phase-ia-trial-for-polycystic-kidney-disease 2025-05-27T15:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/use-of-glp-1-drugs-to-treat-overweight-or-obesity-increased-587-percent-from-2019-to-2024-according-to-new-fair-health-study 2025-05-27T13:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/use-of-glp-1-drugs-to-treat-overweight-or-obesity-increased-587-percent-from-2019-to-2024-according-to-new-fair-health-study 2025-05-27T13:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/rheacell-and-aop-health-partner-to-advance-stem-cell-therapy-for-epidermolysis-bullosa-and-chronic-venous-wounds 2025-05-27T12:57:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rheacell-and-aop-health-partner-to-advance-stem-cell-therapy-for-epidermolysis-bullosa-and-chronic-venous-wounds 2025-05-27T12:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/honeywell-acquires-johnson-matthey-s-catalyst-technologies-for-ps1-8-billion-to-expand-clean-energy-solutions 2025-05-27T12:41:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/honeywell-acquires-johnson-matthey-s-catalyst-technologies-for-ps1-8-billion-to-expand-clean-energy-solutions 2025-05-27T12:41:33+00:00 hourly 0.9 https://trial.medpath.com/news/ku-leuven-spin-off-hemastatx-develops-first-therapy-targeting-root-cause-of-severe-bleeding-disorder 2025-05-27T12:41:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ku-leuven-spin-off-hemastatx-develops-first-therapy-targeting-root-cause-of-severe-bleeding-disorder 2025-05-27T12:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/glycoera-secures-130m-series-b-to-advance-precision-protein-degrader-for-autoimmune-diseases 2025-05-27T12:41:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycoera-secures-130m-series-b-to-advance-precision-protein-degrader-for-autoimmune-diseases 2025-05-27T12:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-rocket-pharmaceuticals-danon-disease-gene-therapy-after-patient-death 2025-05-27T12:41:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-rocket-pharmaceuticals-danon-disease-gene-therapy-after-patient-death 2025-05-27T12:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/epitopea-s-cryptomap-platform-identifies-novel-immunotherapy-targets-in-melanoma-and-nsclc 2025-05-27T12:40:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epitopea-s-cryptomap-platform-identifies-novel-immunotherapy-targets-in-melanoma-and-nsclc 2025-05-27T12:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/kahr-bio-s-dsp107-combination-shows-promise-in-microsatellite-stable-colorectal-cancer-at-asco-2025 2025-05-27T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kahr-bio-s-dsp107-combination-shows-promise-in-microsatellite-stable-colorectal-cancer-at-asco-2025 2025-05-27T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-s-pemgarda-shows-84-covid-19-prevention-efficacy-in-landmark-phase-3-trial 2025-05-27T12:40:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-s-pemgarda-shows-84-covid-19-prevention-efficacy-in-landmark-phase-3-trial 2025-05-27T12:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-presents-six-ai-driven-cancer-research-studies-at-2025-asco-annual-meeting 2025-05-27T12:39:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bostongene-presents-six-ai-driven-cancer-research-studies-at-2025-asco-annual-meeting 2025-05-27T12:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/phanes-therapeutics-doses-first-patient-with-anti-cd73-antibody-mavrostobart-in-combination-therapy-trial 2025-05-27T12:39:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phanes-therapeutics-doses-first-patient-with-anti-cd73-antibody-mavrostobart-in-combination-therapy-trial 2025-05-27T12:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/adc-market-in-nsclc-projected-to-reach-3-9-billion-by-2032-led-by-astrazeneca-s-datroway 2025-05-27T12:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-market-in-nsclc-projected-to-reach-3-9-billion-by-2032-led-by-astrazeneca-s-datroway 2025-05-27T12:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/vectory-therapeutics-appoints-jessica-atkinson-as-chief-business-officer-to-advance-neurodegenerative-disease-pipeline 2025-05-27T12:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vectory-therapeutics-appoints-jessica-atkinson-as-chief-business-officer-to-advance-neurodegenerative-disease-pipeline 2025-05-27T12:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/itm-secures-262-5m-debt-financing-to-support-commercial-launch-of-radiopharmaceutical-itm-11-following-positive-phase-3-results 2025-05-27T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-secures-262-5m-debt-financing-to-support-commercial-launch-of-radiopharmaceutical-itm-11-following-positive-phase-3-results 2025-05-27T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/beiersdorf-partners-with-vincere-biosciences-to-develop-mitophagy-based-anti-aging-skincare-solutions 2025-05-27T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beiersdorf-partners-with-vincere-biosciences-to-develop-mitophagy-based-anti-aging-skincare-solutions 2025-05-27T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/magnitude-biosciences-secures-ps700k-to-advance-high-throughput-drug-discovery-platform 2025-05-27T12:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnitude-biosciences-secures-ps700k-to-advance-high-throughput-drug-discovery-platform 2025-05-27T12:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/applied-cognition-achieves-first-continuous-human-glymphatic-monitoring-unlocking-new-alzheimer-s-drug-targets 2025-05-27T12:37:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-cognition-achieves-first-continuous-human-glymphatic-monitoring-unlocking-new-alzheimer-s-drug-targets 2025-05-27T12:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/selvita-becomes-first-cro-to-license-medicines-discovery-catapult-s-patented-target-engagement-technology 2025-05-27T12:37:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selvita-becomes-first-cro-to-license-medicines-discovery-catapult-s-patented-target-engagement-technology 2025-05-27T12:37:53+00:00 hourly 0.9 https://trial.medpath.com/news/dll3-targeted-therapies-show-promise-for-refractory-small-cell-lung-cancer-despite-clinical-challenges 2025-05-27T12:37:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dll3-targeted-therapies-show-promise-for-refractory-small-cell-lung-cancer-despite-clinical-challenges 2025-05-27T12:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/c4x-discovery-receives-eur8-million-milestone-from-sanofi-for-oral-il-17a-inhibitor-progress 2025-05-27T12:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c4x-discovery-receives-eur8-million-milestone-from-sanofi-for-oral-il-17a-inhibitor-progress 2025-05-27T12:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-s-trusight-oncology-comprehensive-receives-regulatory-approval-in-japan-expanding-precision-cancer-care-access 2025-05-27T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-s-trusight-oncology-comprehensive-receives-regulatory-approval-in-japan-expanding-precision-cancer-care-access 2025-05-27T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-secures-eur-6-3-million-financing-to-support-alfapump-us-commercial-launch 2025-05-27T12:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequana-medical-secures-eur-6-3-million-financing-to-support-alfapump-us-commercial-launch 2025-05-27T12:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-vnvc-launch-77-million-vaccine-manufacturing-facility-in-vietnam 2025-05-27T12:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-vnvc-launch-77-million-vaccine-manufacturing-facility-in-vietnam 2025-05-27T12:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-pivots-clinical-strategy-to-focus-on-cxcr4-targeted-theranostic-oncology-platform 2025-05-27T12:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pentixapharm-pivots-clinical-strategy-to-focus-on-cxcr4-targeted-theranostic-oncology-platform 2025-05-27T12:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/world-adc-san-diego-conference-highlights-growing-industry-focus-on-antibody-drug-conjugates 2025-05-27T09:53:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-adc-san-diego-conference-highlights-growing-industry-focus-on-antibody-drug-conjugates 2025-05-27T09:53:37+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-launches-dayvigo-first-orexin-receptor-antagonist-for-insomnia-treatment-in-china 2025-05-27T09:37:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-launches-dayvigo-first-orexin-receptor-antagonist-for-insomnia-treatment-in-china 2025-05-27T09:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/rnatives-secures-eur1-4m-seed-extension-to-advance-rna-based-gene-regulation-platform 2025-05-27T09:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rnatives-secures-eur1-4m-seed-extension-to-advance-rna-based-gene-regulation-platform 2025-05-27T09:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/mc2-therapeutics-names-trine-ahlgreen-as-ceo-to-drive-global-expansion-of-psoriasis-treatment-wynzora 2025-05-27T09:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mc2-therapeutics-names-trine-ahlgreen-as-ceo-to-drive-global-expansion-of-psoriasis-treatment-wynzora 2025-05-27T09:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/vivoryon-secures-key-u-s-patent-for-varoglutamstat-kidney-disease-treatment-through-2044 2025-05-27T09:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivoryon-secures-key-u-s-patent-for-varoglutamstat-kidney-disease-treatment-through-2044 2025-05-27T09:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/n4-pharma-assembles-expert-leadership-team-to-advance-nuvec-r-gene-delivery-platform 2025-05-27T09:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n4-pharma-assembles-expert-leadership-team-to-advance-nuvec-r-gene-delivery-platform 2025-05-27T09:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-brain-diagnostics-launches-revolutionary-mri-based-dementia-diagnosis-technology-following-fda-and-uk-regulatory-approvals 2025-05-27T09:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-brain-diagnostics-launches-revolutionary-mri-based-dementia-diagnosis-technology-following-fda-and-uk-regulatory-approvals 2025-05-27T09:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-fgfr-inhibitors-show-promise-for-pediatric-brain-tumors-in-preclinical-studies 2025-05-27T03:45:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-fgfr-inhibitors-show-promise-for-pediatric-brain-tumors-in-preclinical-studies 2025-05-27T03:45:03+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-500k-grant-to-advance-synthetic-dna-nanoparticles-for-targeted-gene-therapy 2025-05-27T02:21:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-500k-grant-to-advance-synthetic-dna-nanoparticles-for-targeted-gene-therapy 2025-05-27T02:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/mabxience-expands-european-biosimilar-access-through-strategic-partnerships-with-abiogen-pharma-and-corapharm 2025-05-27T02:15:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabxience-expands-european-biosimilar-access-through-strategic-partnerships-with-abiogen-pharma-and-corapharm 2025-05-27T02:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/tokyo-researchers-develop-nasal-covid-vaccine-showing-superior-respiratory-immunity-in-animal-studies 2025-05-27T00:38:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tokyo-researchers-develop-nasal-covid-vaccine-showing-superior-respiratory-immunity-in-animal-studies 2025-05-27T00:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/dual-target-car-t-therapy-shows-promise-for-glioblastoma-with-24-5-month-median-survival 2025-05-27T00:38:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-target-car-t-therapy-shows-promise-for-glioblastoma-with-24-5-month-median-survival 2025-05-27T00:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/chengdu-ucello-biotech-s-uc101-becomes-first-allogeneic-universal-car-t-therapy-to-receive-fda-ind-approval 2025-05-27T00:37:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chengdu-ucello-biotech-s-uc101-becomes-first-allogeneic-universal-car-t-therapy-to-receive-fda-ind-approval 2025-05-27T00:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/argentina-overhauls-drug-approval-process-mandates-placebo-controls-for-vaccine-trials 2025-05-27T00:37:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argentina-overhauls-drug-approval-process-mandates-placebo-controls-for-vaccine-trials 2025-05-27T00:37:08+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-initiates-manufacturing-of-pnkp-inhibitor-for-preclinical-testing 2025-05-27T00:18:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-initiates-manufacturing-of-pnkp-inhibitor-for-preclinical-testing 2025-05-27T00:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/irlab-s-irl757-shows-promising-safety-profile-in-phase-i-trial-for-apathy-treatment-in-neurological-disorders 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irlab-s-irl757-shows-promising-safety-profile-in-phase-i-trial-for-apathy-treatment-in-neurological-disorders 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/juri-biosciences-secures-global-rights-to-klk2-targeted-t-cell-engager-for-metastatic-prostate-cancer-in-210m-deal 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juri-biosciences-secures-global-rights-to-klk2-targeted-t-cell-engager-for-metastatic-prostate-cancer-in-210m-deal 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enanta-pharmaceuticals-files-patent-infringement-lawsuit-against-pfizer-over-paxlovid 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-files-patent-infringement-lawsuit-against-pfizer-over-paxlovid 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-scorpion-s-cancer-drug-stx-478-in-2-5-billion-deal 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-acquires-scorpion-s-cancer-drug-stx-478-in-2-5-billion-deal 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/poxel-s-pxl065-shows-promise-in-preclinical-hypertrophic-cardiomyopathy-study-data-to-be-presented-at-esc-2025 2025-05-26T23:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poxel-s-pxl065-shows-promise-in-preclinical-hypertrophic-cardiomyopathy-study-data-to-be-presented-at-esc-2025 2025-05-26T23:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/liv-hospital-partners-with-university-of-pennsylvania-to-establish-local-car-t-cell-manufacturing-in-turkey 2025-05-26T20:45:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liv-hospital-partners-with-university-of-pennsylvania-to-establish-local-car-t-cell-manufacturing-in-turkey 2025-05-26T20:45:20+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-s-prmt5-inhibitor-lnp7457-shows-promising-safety-profile-in-phase-1-solid-tumor-trial 2025-05-26T20:44:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-s-prmt5-inhibitor-lnp7457-shows-promising-safety-profile-in-phase-1-solid-tumor-trial 2025-05-26T20:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-launches-zero-interest-payment-plan-for-high-cost-cholesterol-drug-inclisiran-in-india 2025-05-26T20:44:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-launches-zero-interest-payment-plan-for-high-cost-cholesterol-drug-inclisiran-in-india 2025-05-26T20:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-shows-superior-efficacy-in-steroid-refractory-chronic-gvhd-with-38-month-median-failure-free-survival 2025-05-26T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxolitinib-shows-superior-efficacy-in-steroid-refractory-chronic-gvhd-with-38-month-median-failure-free-survival 2025-05-26T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/nextcell-pharma-secures-us-patent-for-msc-prediction-algorithm-to-personalize-cell-therapy 2025-05-26T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcell-pharma-secures-us-patent-for-msc-prediction-algorithm-to-personalize-cell-therapy 2025-05-26T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/lunit-presents-12-ai-powered-studies-at-asco-2025-demonstrating-enhanced-cancer-treatment-selection 2025-05-26T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunit-presents-12-ai-powered-studies-at-asco-2025-demonstrating-enhanced-cancer-treatment-selection 2025-05-26T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-completes-patient-enrollment-in-phase-1-pivotal-study-for-recombinant-human-natural-killer-cell-therapy 2025-05-26T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huonslab-completes-patient-enrollment-in-phase-1-pivotal-study-for-recombinant-human-natural-killer-cell-therapy 2025-05-26T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/iran-becomes-first-asian-country-to-develop-electrochemotherapy-cancer-treatment-technology 2025-05-26T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-becomes-first-asian-country-to-develop-electrochemotherapy-cancer-treatment-technology 2025-05-26T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/prestige-biopharma-will-join-hands-with-global-pharmaceutical-company-teva-to-launch 2025-05-26T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prestige-biopharma-will-join-hands-with-global-pharmaceutical-company-teva-to-launch 2025-05-26T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/cornerstone-robotics-secures-70m-series-c-to-challenge-da-vinci-s-surgical-robot-dominance 2025-05-26T16:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cornerstone-robotics-secures-70m-series-c-to-challenge-da-vinci-s-surgical-robot-dominance 2025-05-26T16:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/medipharm-labs-begins-production-of-cannabis-metered-dose-inhalers-for-european-market-expansion 2025-05-26T16:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipharm-labs-begins-production-of-cannabis-metered-dose-inhalers-for-european-market-expansion 2025-05-26T16:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-positions-australia-as-strategic-alternative-for-us-biotech-clinical-trials-amid-regulatory-uncertainty 2025-05-26T16:15:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avance-clinical-positions-australia-as-strategic-alternative-for-us-biotech-clinical-trials-amid-regulatory-uncertainty 2025-05-26T16:15:49+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitors-transform-polycythemia-vera-treatment-as-novel-therapies-emerge 2025-05-26T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitors-transform-polycythemia-vera-treatment-as-novel-therapies-emerge 2025-05-26T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-completes-enrollment-in-phase-1-trial-for-recombinant-hyaluronidase-eyes-2025-regulatory-filing 2025-05-26T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huonslab-completes-enrollment-in-phase-1-trial-for-recombinant-hyaluronidase-eyes-2025-regulatory-filing 2025-05-26T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/madras-diabetes-research-foundation-partners-with-russia-s-almazov-centre-for-ai-driven-diabetes-research 2025-05-26T12:45:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/madras-diabetes-research-foundation-partners-with-russia-s-almazov-centre-for-ai-driven-diabetes-research 2025-05-26T12:45:37+00:00 hourly 0.9 https://trial.medpath.com/news/biotalys-appoints-luc-van-fraeyenhoven-as-cfo-to-lead-financial-strategy-during-product-commercialization-phase 2025-05-26T11:44:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotalys-appoints-luc-van-fraeyenhoven-as-cfo-to-lead-financial-strategy-during-product-commercialization-phase 2025-05-26T11:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/brandon-capital-opens-second-5m-funding-round-for-dementia-innovation-program 2025-05-26T08:46:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brandon-capital-opens-second-5m-funding-round-for-dementia-innovation-program 2025-05-26T08:46:27+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-predicts-first-ai-designed-drugs-to-reach-market-by-2030 2025-05-26T08:46:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-predicts-first-ai-designed-drugs-to-reach-market-by-2030 2025-05-26T08:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/seqone-genomics-secures-eur20-million-to-accelerate-ai-powered-ngs-platform-for-personalized-medicine 2025-05-26T08:46:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seqone-genomics-secures-eur20-million-to-accelerate-ai-powered-ngs-platform-for-personalized-medicine 2025-05-26T08:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-steincares-to-commercialize-ranibizumab-biosimilar-across-latin-america 2025-05-26T08:14:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-partners-with-steincares-to-commercialize-ranibizumab-biosimilar-across-latin-america 2025-05-26T08:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-biotherapeutics-chairman-ross-haghighat-resigns-as-company-advances-type-1-diabetes-cell-therapy 2025-05-26T07:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-biotherapeutics-chairman-ross-haghighat-resigns-as-company-advances-type-1-diabetes-cell-therapy 2025-05-26T07:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/abbisko-s-fgfr4-inhibitor-irpagratinib-receives-china-s-breakthrough-therapy-designation-for-hepatocellular-carcinoma 2025-05-26T05:16:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbisko-s-fgfr4-inhibitor-irpagratinib-receives-china-s-breakthrough-therapy-designation-for-hepatocellular-carcinoma 2025-05-26T05:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-secures-strategic-china-patent-to-expand-asian-market-presence 2025-05-26T04:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recce-pharmaceuticals-secures-strategic-china-patent-to-expand-asian-market-presence 2025-05-26T04:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-models-show-high-accuracy-in-identifying-severe-pediatric-pneumonia-cases 2025-05-26T04:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-models-show-high-accuracy-in-identifying-severe-pediatric-pneumonia-cases 2025-05-26T04:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-eftilagimod-alpha-combination-meets-primary-endpoint-in-phase-ii-soft-tissue-sarcoma-trial 2025-05-26T00:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-s-eftilagimod-alpha-combination-meets-primary-endpoint-in-phase-ii-soft-tissue-sarcoma-trial 2025-05-26T00:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/cuban-biotech-company-labiofam-s-biorat-rodenticide-shows-success-in-barbados-pilot-study 2025-05-25T20:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuban-biotech-company-labiofam-s-biorat-rodenticide-shows-success-in-barbados-pilot-study 2025-05-25T20:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/grandpharma-s-gpn01768-receives-macao-approval-for-demodex-blepharitis-treatment 2025-05-25T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grandpharma-s-gpn01768-receives-macao-approval-for-demodex-blepharitis-treatment 2025-05-25T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-revolutionizes-breast-cancer-treatment-two-week-test-predicts-relapse-risk-and-spares-patients-from-unnecessary-chemotherapy 2025-05-25T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-testing-revolutionizes-breast-cancer-treatment-two-week-test-predicts-relapse-risk-and-spares-patients-from-unnecessary-chemotherapy 2025-05-25T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-to-present-first-clinical-data-for-next-generation-alk-inhibitor-nvl-655-at-aacr-nci-eortc-symposium 2025-05-25T16:37:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-to-present-first-clinical-data-for-next-generation-alk-inhibitor-nvl-655-at-aacr-nci-eortc-symposium 2025-05-25T16:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-approves-label-updates-for-sanofi-s-rare-disease-therapies-fabrazyme-and-aldurazyme 2025-05-25T12:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-approves-label-updates-for-sanofi-s-rare-disease-therapies-fabrazyme-and-aldurazyme 2025-05-25T12:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-s-promarkerendo-blood-test-achieves-90-accuracy-in-early-endometriosis-detection 2025-05-25T11:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomics-international-s-promarkerendo-blood-test-achieves-90-accuracy-in-early-endometriosis-detection 2025-05-25T11:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-myeloma-treatment-landscape-shows-promise-with-novel-combination-therapies-in-recent-clinical-trials 2025-05-25T06:36:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-myeloma-treatment-landscape-shows-promise-with-novel-combination-therapies-in-recent-clinical-trials 2025-05-25T06:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/axle-health-raises-10m-series-a-to-scale-ai-powered-home-healthcare-platform 2025-05-25T04:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axle-health-raises-10m-series-a-to-scale-ai-powered-home-healthcare-platform 2025-05-25T04:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-strikes-6-billion-deal-with-3sbio-as-remegen-raises-hk-796-million-in-premium-placement 2025-05-25T04:36:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-strikes-6-billion-deal-with-3sbio-as-remegen-raises-hk-796-million-in-premium-placement 2025-05-25T04:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/ruxoprubart-achieves-primary-endpoints-in-phase-2-trial-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-25T03:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxoprubart-achieves-primary-endpoints-in-phase-2-trial-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-25T03:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/global-rheumatoid-arthritis-incidence-rises-13-2-over-three-decades-despite-declining-mortality 2025-05-25T02:36:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-rheumatoid-arthritis-incidence-rises-13-2-over-three-decades-despite-declining-mortality 2025-05-25T02:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/psma-pet-imaging-transforms-prostate-cancer-management-with-multiple-fda-approved-agents 2025-05-25T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psma-pet-imaging-transforms-prostate-cancer-management-with-multiple-fda-approved-agents 2025-05-25T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/c-diff-advocates-highlight-critical-role-of-pharmacists-and-public-health-infrastructure-at-national-summit 2025-05-25T02:16:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-diff-advocates-highlight-critical-role-of-pharmacists-and-public-health-infrastructure-at-national-summit 2025-05-25T02:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/indian-pharma-companies-advance-semaglutide-development-as-cdsco-approves-clinical-trial-protocols 2025-05-25T00:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-pharma-companies-advance-semaglutide-development-as-cdsco-approves-clinical-trial-protocols 2025-05-25T00:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-launches-genio-neurostimulation-therapy-for-sleep-apnea-in-middle-east 2025-05-25T00:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-launches-genio-neurostimulation-therapy-for-sleep-apnea-in-middle-east 2025-05-25T00:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/sahpra-approves-first-who-listed-mpox-diagnostic-test-as-south-africa-reports-31-cases 2025-05-25T00:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sahpra-approves-first-who-listed-mpox-diagnostic-test-as-south-africa-reports-31-cases 2025-05-25T00:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-60-of-eligible-patients-not-receiving-adjuvant-abemaciclib-for-high-risk-early-breast-cancer 2025-05-25T00:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-60-of-eligible-patients-not-receiving-adjuvant-abemaciclib-for-high-risk-early-breast-cancer 2025-05-25T00:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/protein-therapeutics-market-surges-to-400-billion-as-20-new-drugs-gain-approval-in-2023 2025-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protein-therapeutics-market-surges-to-400-billion-as-20-new-drugs-gain-approval-in-2023 2025-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/exosome-therapeutics-field-advances-toward-clinical-trials-as-industry-prepares-for-regulatory-milestones 2025-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exosome-therapeutics-field-advances-toward-clinical-trials-as-industry-prepares-for-regulatory-milestones 2025-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ku-leuven-researchers-develop-dual-agent-method-to-permanently-silence-hiv-virus 2025-05-24T18:14:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ku-leuven-researchers-develop-dual-agent-method-to-permanently-silence-hiv-virus 2025-05-24T18:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-allogene-s-allocar-t-studies-after-safety-investigation-clears-manufacturing-process 2025-05-24T16:44:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-allogene-s-allocar-t-studies-after-safety-investigation-clears-manufacturing-process 2025-05-24T16:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/mynd-life-sciences-settles-3-5m-debenture-through-equity-issuance-to-advance-depression-biomarker-development 2025-05-24T16:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mynd-life-sciences-settles-3-5m-debenture-through-equity-issuance-to-advance-depression-biomarker-development 2025-05-24T16:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/philippines-accelerates-african-swine-fever-and-avian-influenza-vaccine-approvals-with-enhanced-da-fda-collaboration 2025-05-24T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philippines-accelerates-african-swine-fever-and-avian-influenza-vaccine-approvals-with-enhanced-da-fda-collaboration 2025-05-24T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/community-pneumococcal-vaccination-program-reduces-pneumonia-deaths-by-25-in-japanese-elderly-population 2025-05-24T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-pneumococcal-vaccination-program-reduces-pneumonia-deaths-by-25-in-japanese-elderly-population 2025-05-24T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/mskai-spine-imaging-software-receives-fda-510-k-clearance-for-lumbar-mri-analysis 2025-05-24T16:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mskai-spine-imaging-software-receives-fda-510-k-clearance-for-lumbar-mri-analysis 2025-05-24T16:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-withdraws-covid-19-influenza-combination-vaccine-application-following-fda-data-request 2025-05-24T13:45:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-withdraws-covid-19-influenza-combination-vaccine-application-following-fda-data-request 2025-05-24T13:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-schedules-june-2025-investor-conference-presentations-to-update-on-engineered-cell-therapy-pipeline 2025-05-24T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-schedules-june-2025-investor-conference-presentations-to-update-on-engineered-cell-therapy-pipeline 2025-05-24T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/hsk21542-demonstrates-superior-efficacy-in-two-phase-3-trials-for-postoperative-pain-management 2025-05-24T12:36:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hsk21542-demonstrates-superior-efficacy-in-two-phase-3-trials-for-postoperative-pain-management 2025-05-24T12:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/monteloeder-s-nutroxsun-shows-promise-in-clinical-trial-for-uv-induced-skin-protection 2025-05-24T12:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monteloeder-s-nutroxsun-shows-promise-in-clinical-trial-for-uv-induced-skin-protection 2025-05-24T12:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-braftovi-combination-therapy-halves-death-risk-in-braf-mutant-metastatic-colorectal-cancer 2025-05-24T09:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-braftovi-combination-therapy-halves-death-risk-in-braf-mutant-metastatic-colorectal-cancer 2025-05-24T09:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/adm-s-priome-mh-postbiotic-shows-metabolic-benefits-in-canine-clinical-trial 2025-05-24T08:45:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adm-s-priome-mh-postbiotic-shows-metabolic-benefits-in-canine-clinical-trial 2025-05-24T08:45:11+00:00 hourly 0.9 https://trial.medpath.com/news/braid-trial-shows-additional-imaging-could-triple-breast-cancer-detection-in-women-with-dense-breasts 2025-05-24T06:45:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/braid-trial-shows-additional-imaging-could-triple-breast-cancer-detection-in-women-with-dense-breasts 2025-05-24T06:45:20+00:00 hourly 0.9 https://trial.medpath.com/news/elixir-medical-s-dynamx-bioadaptor-shows-sustained-clinical-benefits-over-drug-eluting-stents-at-three-years 2025-05-24T06:45:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elixir-medical-s-dynamx-bioadaptor-shows-sustained-clinical-benefits-over-drug-eluting-stents-at-three-years 2025-05-24T06:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/bio-path-holdings-reports-clinical-progress-across-cancer-pipeline-with-promising-patient-responses 2025-05-24T03:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-path-holdings-reports-clinical-progress-across-cancer-pipeline-with-promising-patient-responses 2025-05-24T03:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-s-maha-report-calls-for-sweeping-reforms-to-address-childhood-health-crisis 2025-05-24T02:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-s-maha-report-calls-for-sweeping-reforms-to-address-childhood-health-crisis 2025-05-24T02:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/hkumed-s-combined-locoregional-immunotherapy-achieves-46-complete-response-rate-in-advanced-liver-cancer 2025-05-24T00:45:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hkumed-s-combined-locoregional-immunotherapy-achieves-46-complete-response-rate-in-advanced-liver-cancer 2025-05-24T00:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-discontinues-birtamimab-development-after-phase-3-failure-in-al-amyloidosis 2025-05-24T00:44:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prothena-discontinues-birtamimab-development-after-phase-3-failure-in-al-amyloidosis 2025-05-24T00:44:51+00:00 hourly 0.9 https://trial.medpath.com/news/enhertu-receives-first-ever-time-limited-reimbursement-for-gastric-cancer-in-canada 2025-05-24T00:44:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhertu-receives-first-ever-time-limited-reimbursement-for-gastric-cancer-in-canada 2025-05-24T00:44:48+00:00 hourly 0.9 https://trial.medpath.com/news/tandem-diabetes-care-settles-patent-dispute-with-roche-for-36-million 2025-05-24T00:44:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tandem-diabetes-care-settles-patent-dispute-with-roche-for-36-million 2025-05-24T00:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-bio-expands-tvgn-489-pipeline-to-include-patients-65-and-older-targeting-1-billion-launch-year-revenue 2025-05-24T00:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tevogen-bio-expands-tvgn-489-pipeline-to-include-patients-65-and-older-targeting-1-billion-launch-year-revenue 2025-05-24T00:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-files-for-300-million-ipo-to-advance-ai-powered-precision-oncology-platform 2025-05-24T00:16:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-files-for-300-million-ipo-to-advance-ai-powered-precision-oncology-platform 2025-05-24T00:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/ziftomenib-shows-promise-in-pivotal-komet-001-trial-for-relapsed-refractory-npm1-mutant-aml 2025-05-24T00:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ziftomenib-shows-promise-in-pivotal-komet-001-trial-for-relapsed-refractory-npm1-mutant-aml 2025-05-24T00:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-octopus-trial-offers-new-hope-for-progressive-multiple-sclerosis-patients 2025-05-24T00:15:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-octopus-trial-offers-new-hope-for-progressive-multiple-sclerosis-patients 2025-05-24T00:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/gv20-therapeutics-to-present-ai-designed-immune-checkpoint-inhibitor-data-for-advanced-melanoma-at-asco-2025 2025-05-24T00:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gv20-therapeutics-to-present-ai-designed-immune-checkpoint-inhibitor-data-for-advanced-melanoma-at-asco-2025 2025-05-24T00:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-therapeutics-abx-002-shows-promising-phase-1-results-for-depression-treatment 2025-05-24T00:15:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autobahn-therapeutics-abx-002-shows-promising-phase-1-results-for-depression-treatment 2025-05-24T00:15:06+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-sees-wave-of-board-appointments-as-companies-strengthen-leadership 2025-05-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-sees-wave-of-board-appointments-as-companies-strengthen-leadership 2025-05-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-invests-25-million-in-pharmazz-expanding-stake-to-22-7-and-securing-key-drug-rights 2025-05-23T21:45:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-invests-25-million-in-pharmazz-expanding-stake-to-22-7-and-securing-key-drug-rights 2025-05-23T21:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-lower-immune-related-adverse-events-in-latin-american-liver-cancer-patients-treated-with-atezolizumab-bevacizumab 2025-05-23T21:45:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-lower-immune-related-adverse-events-in-latin-american-liver-cancer-patients-treated-with-atezolizumab-bevacizumab 2025-05-23T21:45:05+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-submits-lp-8-1-targeting-covid-19-vaccine-to-fda-for-2025-2026-season 2025-05-23T20:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-submits-lp-8-1-targeting-covid-19-vaccine-to-fda-for-2025-2026-season 2025-05-23T20:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/lg-chem-s-aveo-pharmaceuticals-sues-hetero-labs-over-kidney-cancer-drug-patent-infringement 2025-05-23T20:36:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lg-chem-s-aveo-pharmaceuticals-sues-hetero-labs-over-kidney-cancer-drug-patent-infringement 2025-05-23T20:36:54+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-confirms-rivaroxaban-s-safety-and-efficacy-for-extended-use-in-children-with-venous-thromboembolism 2025-05-23T20:22:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-confirms-rivaroxaban-s-safety-and-efficacy-for-extended-use-in-children-with-venous-thromboembolism 2025-05-23T20:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-qamzova-china-developed-long-acting-injectable-painkiller-to-combat-opioid-crisis 2025-05-23T20:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-qamzova-china-developed-long-acting-injectable-painkiller-to-combat-opioid-crisis 2025-05-23T20:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/enhanced-premedication-protocol-reduces-infusion-reactions-in-nsclc-patients-receiving-amivantamab 2025-05-23T20:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhanced-premedication-protocol-reduces-infusion-reactions-in-nsclc-patients-receiving-amivantamab 2025-05-23T20:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-spray-foralumab-shows-promise-in-reducing-brain-inflammation-in-alzheimer-s-patient 2025-05-23T19:46:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-spray-foralumab-shows-promise-in-reducing-brain-inflammation-in-alzheimer-s-patient 2025-05-23T19:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-reveals-corticorelin-as-active-substance-in-c-ptbe-01-with-billion-dollar-market-potential 2025-05-23T19:14:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curatis-reveals-corticorelin-as-active-substance-in-c-ptbe-01-with-billion-dollar-market-potential 2025-05-23T19:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-first-mek-inhibitor-for-nf1-associated-plexiform-neurofibromas-in-adults-and-children 2025-05-23T17:17:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-first-mek-inhibitor-for-nf1-associated-plexiform-neurofibromas-in-adults-and-children 2025-05-23T17:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/ema-restricts-azithromycin-use-to-combat-rising-antimicrobial-resistance 2025-05-23T16:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-restricts-azithromycin-use-to-combat-rising-antimicrobial-resistance 2025-05-23T16:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-10-minute-technique-loads-mrna-into-exosomes-using-fusogenic-cubosomes 2025-05-23T16:49:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-10-minute-technique-loads-mrna-into-exosomes-using-fusogenic-cubosomes 2025-05-23T16:49:35+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-enhance-lentiviral-vector-potency-for-liver-gene-therapy 2025-05-23T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-enhance-lentiviral-vector-potency-for-liver-gene-therapy 2025-05-23T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/northx-biologics-secures-strategic-investment-from-signet-healthcare-partners-to-accelerate-global-expansion 2025-05-23T16:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northx-biologics-secures-strategic-investment-from-signet-healthcare-partners-to-accelerate-global-expansion 2025-05-23T16:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-blood-test-promises-rapid-diagnosis-for-thousands-of-rare-genetic-diseases-in-children 2025-05-23T16:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-blood-test-promises-rapid-diagnosis-for-thousands-of-rare-genetic-diseases-in-children 2025-05-23T16:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/merck-defends-current-gardasil-9-dosing-amid-regulatory-discussions-on-single-dose-regimen 2025-05-23T16:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-defends-current-gardasil-9-dosing-amid-regulatory-discussions-on-single-dose-regimen 2025-05-23T16:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/orion-and-shilpa-medicare-partner-to-bring-recombinant-human-albumin-to-european-market 2025-05-23T16:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orion-and-shilpa-medicare-partner-to-bring-recombinant-human-albumin-to-european-market 2025-05-23T16:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-october-2025-decision-date-for-xbrane-s-ranibizumab-biosimilar-application 2025-05-23T16:48:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-october-2025-decision-date-for-xbrane-s-ranibizumab-biosimilar-application 2025-05-23T16:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-develops-ai-designed-enpp1-inhibitor-ism5939-for-cancer-immunotherapy 2025-05-23T16:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-develops-ai-designed-enpp1-inhibitor-ism5939-for-cancer-immunotherapy 2025-05-23T16:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/texas-a-m-researcher-s-umbilical-cord-cell-therapy-shows-promise-for-als-treatment-in-clinical-trials 2025-05-23T16:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-a-m-researcher-s-umbilical-cord-cell-therapy-shows-promise-for-als-treatment-in-clinical-trials 2025-05-23T16:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/cinclus-pharma-and-zentiva-form-eur220-million-partnership-for-novel-gerd-treatment-in-europe 2025-05-23T16:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cinclus-pharma-and-zentiva-form-eur220-million-partnership-for-novel-gerd-treatment-in-europe 2025-05-23T16:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-phraxis-endoforcetm-connector-advancing-hemodialysis-access-technology 2025-05-23T16:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-phraxis-endoforcetm-connector-advancing-hemodialysis-access-technology 2025-05-23T16:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partners-with-broad-clinical-labs-to-advance-sbx-sequencing-for-critically-ill-newborns 2025-05-23T14:46:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-partners-with-broad-clinical-labs-to-advance-sbx-sequencing-for-critically-ill-newborns 2025-05-23T14:46:18+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-receives-1m-cirm-milestone-payment-as-senti-202-car-nk-therapy-shows-promising-early-results-in-blood-cancers 2025-05-23T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-receives-1m-cirm-milestone-payment-as-senti-202-car-nk-therapy-shows-promising-early-results-in-blood-cancers 2025-05-23T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/mtf-biologics-and-kolosis-bio-introduce-novel-allografts-to-advance-cardiac-surgery-outcomes 2025-05-23T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mtf-biologics-and-kolosis-bio-introduce-novel-allografts-to-advance-cardiac-surgery-outcomes 2025-05-23T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/indoco-remedies-receives-fda-approval-for-generic-allopurinol-tablets-to-treat-high-uric-acid-levels 2025-05-23T12:41:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indoco-remedies-receives-fda-approval-for-generic-allopurinol-tablets-to-treat-high-uric-acid-levels 2025-05-23T12:41:32+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-base-editing-therapy-successfully-cures-thalassemia-in-four-children 2025-05-23T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-base-editing-therapy-successfully-cures-thalassemia-in-four-children 2025-05-23T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-invests-in-aging-research-a-550-million-bet-on-the-future-of-drug-development 2025-05-23T12:39:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-invests-in-aging-research-a-550-million-bet-on-the-future-of-drug-development 2025-05-23T12:39:12+00:00 hourly 0.9 https://trial.medpath.com/news/ai-transforms-real-world-data-into-regulatory-grade-evidence-for-ophthalmology-research 2025-05-23T12:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-transforms-real-world-data-into-regulatory-grade-evidence-for-ophthalmology-research 2025-05-23T12:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-patent-invalidation-of-uniqure-s-hemgenix-gene-therapy-in-pfizer-challenge 2025-05-23T11:16:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-patent-invalidation-of-uniqure-s-hemgenix-gene-therapy-in-pfizer-challenge 2025-05-23T11:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/mindhyve-ai-partners-with-islamabad-diagnostic-centre-to-deploy-agi-powered-diagnostic-intelligence-across-pakistan 2025-05-23T10:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindhyve-ai-partners-with-islamabad-diagnostic-centre-to-deploy-agi-powered-diagnostic-intelligence-across-pakistan 2025-05-23T10:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/duke-study-shows-enzalutamide-combination-extends-survival-by-30-in-metastatic-prostate-cancer 2025-05-23T09:43:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-study-shows-enzalutamide-combination-extends-survival-by-30-in-metastatic-prostate-cancer 2025-05-23T09:43:01+00:00 hourly 0.9 https://trial.medpath.com/news/ulefnersen-shows-unprecedented-recovery-in-young-patients-with-rare-fus-als 2025-05-23T08:46:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ulefnersen-shows-unprecedented-recovery-in-young-patients-with-rare-fus-als 2025-05-23T08:46:21+00:00 hourly 0.9 https://trial.medpath.com/news/nykode-therapeutics-presents-promising-immunotherapy-data-for-hpv16-positive-cancer-and-solid-tumors-at-asco-2025 2025-05-23T08:45:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nykode-therapeutics-presents-promising-immunotherapy-data-for-hpv16-positive-cancer-and-solid-tumors-at-asco-2025 2025-05-23T08:45:31+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-appeals-to-supreme-court-over-fda-s-fast-track-denial-for-gastroparesis-drug 2025-05-23T08:44:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-appeals-to-supreme-court-over-fda-s-fast-track-denial-for-gastroparesis-drug 2025-05-23T08:44:51+00:00 hourly 0.9 https://trial.medpath.com/news/fujitsu-and-thers-successfully-deploy-ai-to-accelerate-clinical-trial-recruitment-and-combat-drug-loss-in-japan 2025-05-23T08:12:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujitsu-and-thers-successfully-deploy-ai-to-accelerate-clinical-trial-recruitment-and-combat-drug-loss-in-japan 2025-05-23T08:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/gene-editing-faces-uncertainty-as-crispr-companies-navigate-regulatory-challenges 2025-05-23T07:38:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-editing-faces-uncertainty-as-crispr-companies-navigate-regulatory-challenges 2025-05-23T07:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/mythic-therapeutics-mytx-011-shows-promising-efficacy-in-phase-1-trial-for-advanced-nsclc 2025-05-23T05:43:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mythic-therapeutics-mytx-011-shows-promising-efficacy-in-phase-1-trial-for-advanced-nsclc 2025-05-23T05:43:40+00:00 hourly 0.9 https://trial.medpath.com/news/gntbm-presents-promising-preclinical-data-for-novel-epigenetic-immune-activator-at-asco-2025 2025-05-23T04:44:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gntbm-presents-promising-preclinical-data-for-novel-epigenetic-immune-activator-at-asco-2025 2025-05-23T04:44:48+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-shows-promise-in-treating-car-t-cell-therapy-induced-parkinsonism-in-multiple-myeloma 2025-05-23T04:44:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxolitinib-shows-promise-in-treating-car-t-cell-therapy-induced-parkinsonism-in-multiple-myeloma 2025-05-23T04:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-pfizer-s-victory-in-gene-therapy-patent-dispute-for-hemophilia-treatment 2025-05-23T04:43:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-pfizer-s-victory-in-gene-therapy-patent-dispute-for-hemophilia-treatment 2025-05-23T04:43:59+00:00 hourly 0.9 https://trial.medpath.com/news/maha-commission-proposes-comprehensive-pediatric-drug-safety-research-initiative 2025-05-23T04:43:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maha-commission-proposes-comprehensive-pediatric-drug-safety-research-initiative 2025-05-23T04:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/e7386-shows-promising-results-in-advanced-endometrial-cancer-trial-with-30-response-rate 2025-05-23T04:43:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/e7386-shows-promising-results-in-advanced-endometrial-cancer-trial-with-30-response-rate 2025-05-23T04:43:50+00:00 hourly 0.9 https://trial.medpath.com/news/dual-targeting-radiopharmaceutical-shows-89-response-rate-in-advanced-cancer-trial 2025-05-23T04:16:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-targeting-radiopharmaceutical-shows-89-response-rate-in-advanced-cancer-trial 2025-05-23T04:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/servier-to-present-phase-3-data-on-idh-mutated-cancer-therapies-at-asco-2025 2025-05-23T04:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-to-present-phase-3-data-on-idh-mutated-cancer-therapies-at-asco-2025 2025-05-23T04:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-to-present-14-real-world-oncology-data-studies-at-asco-2025 2025-05-23T02:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-to-present-14-real-world-oncology-data-studies-at-asco-2025 2025-05-23T02:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-expand-u-s-manufacturing-operations-creating-thousands-of-new-jobs 2025-05-23T02:47:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-companies-expand-u-s-manufacturing-operations-creating-thousands-of-new-jobs 2025-05-23T02:47:05+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-advances-sgx943-as-novel-antibiotic-alternative-to-combat-drug-resistant-bacterial-infections 2025-05-23T02:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-advances-sgx943-as-novel-antibiotic-alternative-to-combat-drug-resistant-bacterial-infections 2025-05-23T02:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/auxilium-biotechnologies-initiates-pivotal-trial-for-neurospan-bridge-nerve-regeneration-device 2025-05-23T01:47:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auxilium-biotechnologies-initiates-pivotal-trial-for-neurospan-bridge-nerve-regeneration-device 2025-05-23T01:47:09+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-pharmaceuticals-unveils-promising-final-data-from-gavreto-and-rezlidhia-clinical-trials-at-asco-and-eha-2025 2025-05-23T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-pharmaceuticals-unveils-promising-final-data-from-gavreto-and-rezlidhia-clinical-trials-at-asco-and-eha-2025 2025-05-23T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-reports-promising-results-for-zanzalintinib-combination-in-advanced-kidney-cancer 2025-05-23T01:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-reports-promising-results-for-zanzalintinib-combination-in-advanced-kidney-cancer 2025-05-23T01:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/miradx-and-ucla-to-present-groundbreaking-research-on-microrna-based-predictive-biomarkers-at-asco-2025 2025-05-23T00:46:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miradx-and-ucla-to-present-groundbreaking-research-on-microrna-based-predictive-biomarkers-at-asco-2025 2025-05-23T00:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/zepzelca-tecentriq-combination-shows-survival-benefit-in-metastatic-small-cell-lung-cancer 2025-05-23T00:44:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zepzelca-tecentriq-combination-shows-survival-benefit-in-metastatic-small-cell-lung-cancer 2025-05-23T00:44:34+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-reports-promising-results-for-sirp-inhibitors-in-cancer-immunotherapy-trials 2025-05-23T00:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-reports-promising-results-for-sirp-inhibitors-in-cancer-immunotherapy-trials 2025-05-23T00:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/volastra-s-novel-kif18a-inhibitor-shows-promising-results-in-ovarian-cancer-patients 2025-05-23T00:16:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/volastra-s-novel-kif18a-inhibitor-shows-promising-results-in-ovarian-cancer-patients 2025-05-23T00:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/linvoseltamab-combination-therapy-shows-90-response-rate-in-relapsed-refractory-multiple-myeloma 2025-05-23T00:16:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/linvoseltamab-combination-therapy-shows-90-response-rate-in-relapsed-refractory-multiple-myeloma 2025-05-23T00:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/amtagvi-shows-unprecedented-20-five-year-survival-rate-in-advanced-melanoma-patients 2025-05-23T00:15:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amtagvi-shows-unprecedented-20-five-year-survival-rate-in-advanced-melanoma-patients 2025-05-23T00:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/merus-reports-promising-survival-data-for-petosemtamab-keytruda-combination-in-metastatic-head-and-neck-cancer 2025-05-23T00:15:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merus-reports-promising-survival-data-for-petosemtamab-keytruda-combination-in-metastatic-head-and-neck-cancer 2025-05-23T00:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/rwjbarnabas-health-and-rutgers-cancer-institute-to-present-45-groundbreaking-studies-at-asco-2025 2025-05-23T00:15:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rwjbarnabas-health-and-rutgers-cancer-institute-to-present-45-groundbreaking-studies-at-asco-2025 2025-05-23T00:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-onset-diabetes-emerges-as-early-warning-signal-for-pancreatic-cancer-detection 2025-05-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-onset-diabetes-emerges-as-early-warning-signal-for-pancreatic-cancer-detection 2025-05-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/microneedle-technology-emerges-as-game-changer-for-targeted-drug-delivery-and-vaccine-administration 2025-05-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microneedle-technology-emerges-as-game-changer-for-targeted-drug-delivery-and-vaccine-administration 2025-05-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-to-present-groundbreaking-cancer-advances-at-2025-asco-annual-meeting 2025-05-22T23:45:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-to-present-groundbreaking-cancer-advances-at-2025-asco-annual-meeting 2025-05-22T23:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/cizzle-bio-s-ciz1b-blood-test-could-save-medicare-518-million-annually-in-lung-cancer-screening 2025-05-22T23:45:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cizzle-bio-s-ciz1b-blood-test-could-save-medicare-518-million-annually-in-lung-cancer-screening 2025-05-22T23:45:08+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-boehringer-ingelheim-complete-groundbreaking-schizophrenia-research-project 2025-05-22T22:44:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-x-and-boehringer-ingelheim-complete-groundbreaking-schizophrenia-research-project 2025-05-22T22:44:54+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-biologicals-expands-adc-capabilities-with-new-bioconjugation-facility-in-india 2025-05-22T22:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-biologicals-expands-adc-capabilities-with-new-bioconjugation-facility-in-india 2025-05-22T22:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/satellos-reports-promising-efficacy-signals-for-novel-dmd-treatment-in-adult-patients 2025-05-22T22:15:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/satellos-reports-promising-efficacy-signals-for-novel-dmd-treatment-in-adult-patients 2025-05-22T22:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-options-for-smoker-s-lung 2025-05-22T22:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-options-for-smoker-s-lung 2025-05-22T22:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/roche-and-ascidian-forge-1-8-billion-partnership-for-neurological-disease-drug-development 2025-05-22T21:45:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-and-ascidian-forge-1-8-billion-partnership-for-neurological-disease-drug-development 2025-05-22T21:45:24+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-enters-1-3-billion-rna-therapy-partnership-to-expand-genetic-hearing-loss-pipeline 2025-05-22T21:45:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-enters-1-3-billion-rna-therapy-partnership-to-expand-genetic-hearing-loss-pipeline 2025-05-22T21:45:14+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-presents-breakthrough-enhertu-data-at-asco-2025-with-two-late-breaking-phase-3-trials 2025-05-22T21:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-presents-breakthrough-enhertu-data-at-asco-2025-with-two-late-breaking-phase-3-trials 2025-05-22T21:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/lupkynis-based-triple-therapy-shows-superior-proteinuria-reduction-in-lupus-nephritis-patients 2025-05-22T20:38:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupkynis-based-triple-therapy-shows-superior-proteinuria-reduction-in-lupus-nephritis-patients 2025-05-22T20:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/eu-establishes-emergency-compulsory-licensing-framework-for-pharmaceutical-patents-with-key-limitations 2025-05-22T20:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-establishes-emergency-compulsory-licensing-framework-for-pharmaceutical-patents-with-key-limitations 2025-05-22T20:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/setu-secures-eur159589-grant-for-novel-gene-therapy-research-in-fatal-childhood-canavan-disease 2025-05-22T20:38:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/setu-secures-eur159589-grant-for-novel-gene-therapy-research-in-fatal-childhood-canavan-disease 2025-05-22T20:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/nih-scientists-develop-novel-surgical-technique-to-enhance-cell-therapy-for-dry-age-related-macular-degeneration 2025-05-22T20:38:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-scientists-develop-novel-surgical-technique-to-enhance-cell-therapy-for-dry-age-related-macular-degeneration 2025-05-22T20:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/instil-bio-and-immuneonco-advance-pd-l-1xvegf-bispecific-antibody-clinical-development-strategy 2025-05-22T20:37:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/instil-bio-and-immuneonco-advance-pd-l-1xvegf-bispecific-antibody-clinical-development-strategy 2025-05-22T20:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/alteogen-s-aflibercept-biosimilar-eyluxvi-receives-positive-opinion-from-european-medicines-agency 2025-05-22T20:19:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alteogen-s-aflibercept-biosimilar-eyluxvi-receives-positive-opinion-from-european-medicines-agency 2025-05-22T20:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/instil-bio-s-pd-l1xvegf-bispecific-antibody-shows-promise-in-nsclc-driving-48-stock-surge 2025-05-22T20:18:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/instil-bio-s-pd-l1xvegf-bispecific-antibody-shows-promise-in-nsclc-driving-48-stock-surge 2025-05-22T20:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-tax-bill-passes-house-with-pharma-reforms-ira-pill-penalty-remains-unchanged 2025-05-22T20:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-tax-bill-passes-house-with-pharma-reforms-ira-pill-penalty-remains-unchanged 2025-05-22T20:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/dupont-launches-amberchrom-tq1-chromatography-resin-to-advance-oligonucleotide-and-peptide-purification 2025-05-22T20:16:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupont-launches-amberchrom-tq1-chromatography-resin-to-advance-oligonucleotide-and-peptide-purification 2025-05-22T20:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-partners-with-haorui-gene-to-expand-long-read-sequencing-access-across-china 2025-05-22T19:44:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacbio-partners-with-haorui-gene-to-expand-long-read-sequencing-access-across-china 2025-05-22T19:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-d-supplementation-shown-to-slow-biological-aging-in-landmark-vital-trial 2025-05-22T19:44:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitamin-d-supplementation-shown-to-slow-biological-aging-in-landmark-vital-trial 2025-05-22T19:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-sues-neurimmune-over-rights-to-novel-alzheimer-s-bispecific-antibody-technology 2025-05-22T19:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-sues-neurimmune-over-rights-to-novel-alzheimer-s-bispecific-antibody-technology 2025-05-22T19:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/fore-biotherapeutics-secures-38-million-in-series-d-2-financing-to-advance-plixorafenib-clinical-trials 2025-05-22T17:38:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fore-biotherapeutics-secures-38-million-in-series-d-2-financing-to-advance-plixorafenib-clinical-trials 2025-05-22T17:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-drug-prices-double-as-pharmaceutical-industry-shifts-focus-to-rare-diseases 2025-05-22T17:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-drug-prices-double-as-pharmaceutical-industry-shifts-focus-to-rare-diseases 2025-05-22T17:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-centafore-new-imaging-core-lab-to-enhance-clinical-trial-imaging-and-samd-development 2025-05-22T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-launches-centafore-new-imaging-core-lab-to-enhance-clinical-trial-imaging-and-samd-development 2025-05-22T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/rubedo-life-sciences-initiates-first-ever-gpx4-modulator-clinical-trial-for-psoriasis-and-skin-aging 2025-05-22T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rubedo-life-sciences-initiates-first-ever-gpx4-modulator-clinical-trial-for-psoriasis-and-skin-aging 2025-05-22T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/meril-s-myval-thv-series-demonstrates-non-inferiority-in-landmark-head-to-head-tavi-trial 2025-05-22T16:40:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meril-s-myval-thv-series-demonstrates-non-inferiority-in-landmark-head-to-head-tavi-trial 2025-05-22T16:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/cureduchenne-ventures-invests-1m-in-entos-pharmaceuticals-for-novel-duchenne-muscular-dystrophy-gene-therapy 2025-05-22T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cureduchenne-ventures-invests-1m-in-entos-pharmaceuticals-for-novel-duchenne-muscular-dystrophy-gene-therapy 2025-05-22T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-spray-gene-therapy-shows-promise-for-treating-lung-diseases 2025-05-22T16:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-spray-gene-therapy-shows-promise-for-treating-lung-diseases 2025-05-22T16:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/peptide-drug-conjugates-emerge-as-next-generation-cancer-therapeutics-with-over-30-candidates-in-clinical-development 2025-05-22T16:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptide-drug-conjugates-emerge-as-next-generation-cancer-therapeutics-with-over-30-candidates-in-clinical-development 2025-05-22T16:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/kfshrc-and-cellenkos-partner-to-advance-treg-cell-therapies-for-rare-diseases-in-landmark-saudi-us-collaboration 2025-05-22T16:38:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kfshrc-and-cellenkos-partner-to-advance-treg-cell-therapies-for-rare-diseases-in-landmark-saudi-us-collaboration 2025-05-22T16:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/neuropeutics-inc-wins-abbvie-biotech-innovators-award-for-novel-neurodegenerative-disease-therapies 2025-05-22T16:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuropeutics-inc-wins-abbvie-biotech-innovators-award-for-novel-neurodegenerative-disease-therapies 2025-05-22T16:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/large-norwegian-study-finds-no-increased-risk-of-autism-or-adhd-in-children-exposed-to-triptans-during-pregnancy 2025-05-22T16:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-norwegian-study-finds-no-increased-risk-of-autism-or-adhd-in-children-exposed-to-triptans-during-pregnancy 2025-05-22T16:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-prepares-to-launch-phase-2a-trial-of-novel-cannabinoid-based-pain-therapy-for-cancer-patients 2025-05-22T16:25:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyus-life-sciences-prepares-to-launch-phase-2a-trial-of-novel-cannabinoid-based-pain-therapy-for-cancer-patients 2025-05-22T16:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/uk-high-court-rules-amgen-and-samsung-bioepis-soliris-biosimilars-do-not-infringe-alexion-patent 2025-05-22T16:25:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-high-court-rules-amgen-and-samsung-bioepis-soliris-biosimilars-do-not-infringe-alexion-patent 2025-05-22T16:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-acquires-aptoll-from-aptatargets-for-acute-ischemic-stroke-treatment 2025-05-22T16:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-acquires-aptoll-from-aptatargets-for-acute-ischemic-stroke-treatment 2025-05-22T16:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/repronovo-secures-65m-series-a-to-revive-failed-fertility-drug-nolasiban 2025-05-22T16:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repronovo-secures-65m-series-a-to-revive-failed-fertility-drug-nolasiban 2025-05-22T16:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/syantra-expands-ip-portfolio-with-novel-tumor-education-approach-for-cancer-detection-and-treatment 2025-05-22T16:23:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syantra-expands-ip-portfolio-with-novel-tumor-education-approach-for-cancer-detection-and-treatment 2025-05-22T16:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/aptahem-advances-apta-1-to-phase-ii-as-european-pharma-company-expresses-strong-partnership-interest 2025-05-22T16:23:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptahem-advances-apta-1-to-phase-ii-as-european-pharma-company-expresses-strong-partnership-interest 2025-05-22T16:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rejoyn-first-prescription-digital-therapeutic-for-major-depressive-disorder 2025-05-22T16:21:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-rejoyn-first-prescription-digital-therapeutic-for-major-depressive-disorder 2025-05-22T16:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-gremubamab-shows-promise-in-reducing-pseudomonas-infection-in-bronchiectasis-patients 2025-05-22T16:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-gremubamab-shows-promise-in-reducing-pseudomonas-infection-in-bronchiectasis-patients 2025-05-22T16:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/lenvatinib-plus-pd-1-l1-inhibitors-shows-superior-efficacy-over-bevacizumab-combinations-in-unresectable-hepatocellular-carcinoma 2025-05-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenvatinib-plus-pd-1-l1-inhibitors-shows-superior-efficacy-over-bevacizumab-combinations-in-unresectable-hepatocellular-carcinoma 2025-05-22T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neogenomics-launches-c-met-companion-diagnostic-for-advanced-non-small-cell-lung-cancer-treatment 2025-05-22T15:43:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neogenomics-launches-c-met-companion-diagnostic-for-advanced-non-small-cell-lung-cancer-treatment 2025-05-22T15:43:18+00:00 hourly 0.9 https://trial.medpath.com/news/citrin-foundation-and-university-children-s-hospital-zurich-launch-pioneering-center-for-urea-cycle-disorders-research 2025-05-22T14:45:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citrin-foundation-and-university-children-s-hospital-zurich-launch-pioneering-center-for-urea-cycle-disorders-research 2025-05-22T14:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/augustine-therapeutics-appoints-rie-schultz-hansen-as-cso-establishes-copenhagen-subsidiary-to-advance-hdac6-inhibitor-pipeline 2025-05-22T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/augustine-therapeutics-appoints-rie-schultz-hansen-as-cso-establishes-copenhagen-subsidiary-to-advance-hdac6-inhibitor-pipeline 2025-05-22T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-aptar-digital-health-partner-to-develop-ai-algorithms-for-early-detection-of-chronic-kidney-disease 2025-05-22T14:43:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-aptar-digital-health-partner-to-develop-ai-algorithms-for-early-detection-of-chronic-kidney-disease 2025-05-22T14:43:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-streamlines-canadian-drug-importation-process-to-lower-us-prescription-costs 2025-05-22T13:46:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-streamlines-canadian-drug-importation-process-to-lower-us-prescription-costs 2025-05-22T13:46:01+00:00 hourly 0.9 https://trial.medpath.com/news/duke-university-develops-sbi-810-novel-non-opioid-painkiller-targeting-specific-brain-receptors 2025-05-22T13:43:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-university-develops-sbi-810-novel-non-opioid-painkiller-targeting-specific-brain-receptors 2025-05-22T13:43:30+00:00 hourly 0.9 https://trial.medpath.com/news/phase-scientific-secures-34-million-to-advance-urine-based-cancer-diagnostics 2025-05-22T12:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-scientific-secures-34-million-to-advance-urine-based-cancer-diagnostics 2025-05-22T12:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-ceo-steps-down-after-eight-years-as-company-faces-market-pressures 2025-05-22T12:47:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-ceo-steps-down-after-eight-years-as-company-faces-market-pressures 2025-05-22T12:47:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ascletis-ind-for-asc50-a-novel-oral-il-17-inhibitor-for-psoriasis-treatment 2025-05-22T12:47:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ascletis-ind-for-asc50-a-novel-oral-il-17-inhibitor-for-psoriasis-treatment 2025-05-22T12:47:16+00:00 hourly 0.9 https://trial.medpath.com/news/vicore-pharma-s-buloxibutid-shows-superior-anti-fibrotic-activity-for-ipf-treatment-in-new-data 2025-05-22T12:46:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vicore-pharma-s-buloxibutid-shows-superior-anti-fibrotic-activity-for-ipf-treatment-in-new-data 2025-05-22T12:46:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-convenes-expert-panel-to-evaluate-talc-safety-in-food-and-drugs 2025-05-22T12:46:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-convenes-expert-panel-to-evaluate-talc-safety-in-food-and-drugs 2025-05-22T12:46:25+00:00 hourly 0.9 https://trial.medpath.com/news/comac-medical-group-acquires-ilife-consulting-to-strengthen-oncology-and-early-phase-trial-capabilities 2025-05-22T12:45:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comac-medical-group-acquires-ilife-consulting-to-strengthen-oncology-and-early-phase-trial-capabilities 2025-05-22T12:45:43+00:00 hourly 0.9 https://trial.medpath.com/news/vyloy-leads-claudin-18-2-targeted-therapy-revolution-with-60-drug-candidates-in-pipeline 2025-05-22T12:45:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyloy-leads-claudin-18-2-targeted-therapy-revolution-with-60-drug-candidates-in-pipeline 2025-05-22T12:45:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-biopharma-venture-funding-hits-1-1-billion-in-q1-2025-signaling-strong-industry-growth 2025-05-22T12:44:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-biopharma-venture-funding-hits-1-1-billion-in-q1-2025-signaling-strong-industry-growth 2025-05-22T12:44:33+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-to-become-wholly-owned-subsidiary-of-samsung-biologics-in-strategic-restructuring 2025-05-22T12:44:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-to-become-wholly-owned-subsidiary-of-samsung-biologics-in-strategic-restructuring 2025-05-22T12:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-s-rp1-melanoma-therapy-nears-fda-decision-with-july-pdufa-date-as-commercial-infrastructure-readies-for-launch 2025-05-22T12:44:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replimune-s-rp1-melanoma-therapy-nears-fda-decision-with-july-pdufa-date-as-commercial-infrastructure-readies-for-launch 2025-05-22T12:44:24+00:00 hourly 0.9 https://trial.medpath.com/news/malaysia-extends-biocon-biologics-insulin-supply-contract-for-six-additional-months 2025-05-22T12:44:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaysia-extends-biocon-biologics-insulin-supply-contract-for-six-additional-months 2025-05-22T12:44:17+00:00 hourly 0.9 https://trial.medpath.com/news/route-92-medical-s-hipoint-88-reperfusion-system-achieves-record-first-pass-effect-in-stroke-thrombectomy-trial 2025-05-22T12:44:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/route-92-medical-s-hipoint-88-reperfusion-system-achieves-record-first-pass-effect-in-stroke-thrombectomy-trial 2025-05-22T12:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/new-sickle-cell-disease-therapies-expand-options-but-access-barriers-remain 2025-05-22T12:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-sickle-cell-disease-therapies-expand-options-but-access-barriers-remain 2025-05-22T12:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-cryogenic-mass-spectrometry-method-reveals-lipid-nanoparticle-structure-advancing-rna-therapeutics 2025-05-22T12:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-cryogenic-mass-spectrometry-method-reveals-lipid-nanoparticle-structure-advancing-rna-therapeutics 2025-05-22T12:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-advances-lupus-drug-to-phase-iii-despite-mixed-clinical-results 2025-05-22T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-advances-lupus-drug-to-phase-iii-despite-mixed-clinical-results 2025-05-22T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/nanoparticle-based-drug-delivery-systems-show-promise-for-enhancing-cancer-immunotherapy-in-solid-tumors 2025-05-22T11:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoparticle-based-drug-delivery-systems-show-promise-for-enhancing-cancer-immunotherapy-in-solid-tumors 2025-05-22T11:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-study-reveals-ssris-may-enhance-immune-response-against-cancer 2025-05-22T09:36:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-study-reveals-ssris-may-enhance-immune-response-against-cancer 2025-05-22T09:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/elicera-s-itank-armed-car-t-cell-therapy-shows-complete-response-in-lymphoma-patients 2025-05-22T08:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicera-s-itank-armed-car-t-cell-therapy-shows-complete-response-in-lymphoma-patients 2025-05-22T08:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/dual-mtorc1-2-inhibitor-bi-860585-shows-promise-in-phase-i-breast-cancer-trial 2025-05-22T08:37:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-mtorc1-2-inhibitor-bi-860585-shows-promise-in-phase-i-breast-cancer-trial 2025-05-22T08:37:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-designation-to-relief-therapeutics-eb-treatment-rlf-td011 2025-05-22T08:36:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-designation-to-relief-therapeutics-eb-treatment-rlf-td011 2025-05-22T08:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/medipharm-labs-advances-4-5-million-asset-sale-to-strengthen-financial-position-for-international-expansion 2025-05-22T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipharm-labs-advances-4-5-million-asset-sale-to-strengthen-financial-position-for-international-expansion 2025-05-22T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/intalight-s-dream-oct-platform-receives-ce-mark-approval-for-european-market 2025-05-22T08:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intalight-s-dream-oct-platform-receives-ce-mark-approval-for-european-market 2025-05-22T08:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/viz-ai-partners-with-sanofi-and-regeneron-to-deploy-ai-powered-copd-management-solution 2025-05-22T05:44:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viz-ai-partners-with-sanofi-and-regeneron-to-deploy-ai-powered-copd-management-solution 2025-05-22T05:44:25+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-patent-extensions-and-505-b-2-applications-key-pathways-for-post-anda-market-exclusivity 2025-05-22T04:45:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-patent-extensions-and-505-b-2-applications-key-pathways-for-post-anda-market-exclusivity 2025-05-22T04:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/surgeons-complete-world-s-first-human-bladder-transplant-in-groundbreaking-procedure 2025-05-22T04:44:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgeons-complete-world-s-first-human-bladder-transplant-in-groundbreaking-procedure 2025-05-22T04:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/nus-researchers-develop-next-a-revolutionary-gene-delivery-platform-for-cancer-immunotherapy 2025-05-22T04:44:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nus-researchers-develop-next-a-revolutionary-gene-delivery-platform-for-cancer-immunotherapy 2025-05-22T04:44:25+00:00 hourly 0.9 https://trial.medpath.com/news/annji-pharmaceutical-reports-promising-phase-1-2a-results-for-aj201-in-sbma-a-rare-neuromuscular-disease 2025-05-22T04:44:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annji-pharmaceutical-reports-promising-phase-1-2a-results-for-aj201-in-sbma-a-rare-neuromuscular-disease 2025-05-22T04:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-to-spin-off-biosimilar-business-to-focus-on-core-cdmo-services 2025-05-22T04:43:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-to-spin-off-biosimilar-business-to-focus-on-core-cdmo-services 2025-05-22T04:43:46+00:00 hourly 0.9 https://trial.medpath.com/news/international-r-d-partnerships-drive-innovation-and-accessibility-in-generic-drug-development 2025-05-22T04:43:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-r-d-partnerships-drive-innovation-and-accessibility-in-generic-drug-development 2025-05-22T04:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-researchers-discover-drug-treatment-to-triple-donor-heart-preservation-time 2025-05-22T03:43:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-researchers-discover-drug-treatment-to-triple-donor-heart-preservation-time 2025-05-22T03:43:29+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-take-central-role-in-managing-novel-cancer-therapies-as-car-t-and-bispecific-antibodies-transform-treatment-landscape 2025-05-22T02:41:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-take-central-role-in-managing-novel-cancer-therapies-as-car-t-and-bispecific-antibodies-transform-treatment-landscape 2025-05-22T02:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-avenzo-therapeutics-ind-for-avzo-023-a-novel-cdk4-selective-inhibitor-for-advanced-breast-cancer 2025-05-22T00:47:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-avenzo-therapeutics-ind-for-avzo-023-a-novel-cdk4-selective-inhibitor-for-advanced-breast-cancer 2025-05-22T00:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-to-acquire-vigil-neuroscience-for-up-to-600-million-expanding-alzheimer-s-disease-pipeline 2025-05-22T00:47:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-to-acquire-vigil-neuroscience-for-up-to-600-million-expanding-alzheimer-s-disease-pipeline 2025-05-22T00:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-cdsco-approves-two-cancer-drugs-with-phase-iv-trial-requirements 2025-05-22T00:19:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-cdsco-approves-two-cancer-drugs-with-phase-iv-trial-requirements 2025-05-22T00:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-immunotherapy-for-head-and-neck-cancer 2025-05-22T00:15:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-immunotherapy-for-head-and-neck-cancer 2025-05-22T00:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/extracellular-vesicles-emerge-as-dual-players-in-cancer-immunotherapy-resistance-and-treatment-innovation 2025-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extracellular-vesicles-emerge-as-dual-players-in-cancer-immunotherapy-resistance-and-treatment-innovation 2025-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-leadership-to-present-at-major-healthcare-investment-conferences-in-2025 2025-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-leadership-to-present-at-major-healthcare-investment-conferences-in-2025 2025-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-ai-blood-test-artemis-delfi-shows-promise-for-monitoring-pancreatic-cancer-treatment-response 2025-05-21T23:48:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ai-blood-test-artemis-delfi-shows-promise-for-monitoring-pancreatic-cancer-treatment-response 2025-05-21T23:48:42+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-blood-test-achieves-99-accuracy-in-detecting-hpv-associated-head-and-neck-cancers 2025-05-21T23:47:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-blood-test-achieves-99-accuracy-in-detecting-hpv-associated-head-and-neck-cancers 2025-05-21T23:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/childhood-cancer-survivors-face-five-fold-higher-risk-of-kidney-disease-and-hypertension 2025-05-21T23:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/childhood-cancer-survivors-face-five-fold-higher-risk-of-kidney-disease-and-hypertension 2025-05-21T23:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-s-lumify-preservative-free-eye-drops-demonstrate-non-inferiority-in-phase-3-trial 2025-05-21T22:47:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-s-lumify-preservative-free-eye-drops-demonstrate-non-inferiority-in-phase-3-trial 2025-05-21T22:47:11+00:00 hourly 0.9 https://trial.medpath.com/news/onward-medical-advances-brain-computer-interface-technology-with-fifth-successful-implant-for-spinal-cord-injury-patients 2025-05-21T22:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onward-medical-advances-brain-computer-interface-technology-with-fifth-successful-implant-for-spinal-cord-injury-patients 2025-05-21T22:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/repronovo-secures-65-million-series-a-funding-to-advance-novel-reproductive-medicine-therapies 2025-05-21T20:47:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repronovo-secures-65-million-series-a-funding-to-advance-novel-reproductive-medicine-therapies 2025-05-21T20:47:08+00:00 hourly 0.9 https://trial.medpath.com/news/california-s-ab-824-pharmaceutical-patent-settlement-law-faces-permanent-injunction-limiting-enforcement 2025-05-21T20:46:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-s-ab-824-pharmaceutical-patent-settlement-law-faces-permanent-injunction-limiting-enforcement 2025-05-21T20:46:14+00:00 hourly 0.9 https://trial.medpath.com/news/rainbow-children-s-hospital-completes-eighth-zolgensma-gene-therapy-for-spinal-muscular-atrophy-in-india 2025-05-21T20:45:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rainbow-children-s-hospital-completes-eighth-zolgensma-gene-therapy-for-spinal-muscular-atrophy-in-india 2025-05-21T20:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/south-rampart-pharma-secures-new-investment-for-novel-non-opioid-pain-treatment 2025-05-21T20:45:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-rampart-pharma-secures-new-investment-for-novel-non-opioid-pain-treatment 2025-05-21T20:45:16+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-issues-new-warnings-to-teva-and-novartis-over-improper-orange-book-patent-listings 2025-05-21T20:44:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-issues-new-warnings-to-teva-and-novartis-over-improper-orange-book-patent-listings 2025-05-21T20:44:05+00:00 hourly 0.9 https://trial.medpath.com/news/study-identifies-why-venetoclax-based-aml-treatment-fails-in-certain-patients 2025-05-21T20:43:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-identifies-why-venetoclax-based-aml-treatment-fails-in-certain-patients 2025-05-21T20:43:49+00:00 hourly 0.9 https://trial.medpath.com/news/montara-therapeutics-receives-3-3m-grant-from-michael-j-fox-foundation-to-develop-brain-selective-lrrk2-inhibitor-for-parkinson-s 2025-05-21T20:43:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montara-therapeutics-receives-3-3m-grant-from-michael-j-fox-foundation-to-develop-brain-selective-lrrk2-inhibitor-for-parkinson-s 2025-05-21T20:43:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-clinical-trial-of-atia-vision-s-innovative-omnivu-lens-system-for-cataract-patients 2025-05-21T20:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-clinical-trial-of-atia-vision-s-innovative-omnivu-lens-system-for-cataract-patients 2025-05-21T20:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funded-teams-develop-precision-gene-delivery-systems-for-neural-cells 2025-05-21T18:13:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funded-teams-develop-precision-gene-delivery-systems-for-neural-cells 2025-05-21T18:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/senores-pharmaceuticals-acquires-anda-for-enalapril-maleate-tablets-from-wockhardt 2025-05-21T16:53:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senores-pharmaceuticals-acquires-anda-for-enalapril-maleate-tablets-from-wockhardt 2025-05-21T16:53:37+00:00 hourly 0.9 https://trial.medpath.com/news/resistance-to-til-therapy-in-lung-cancer-mediated-by-clonal-t-cell-loss-and-neoantigen-escape 2025-05-21T16:52:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resistance-to-til-therapy-in-lung-cancer-mediated-by-clonal-t-cell-loss-and-neoantigen-escape 2025-05-21T16:52:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-supports-novel-endpoints-for-abli-therapeutics-risvodetinib-phase-3-trial-in-parkinson-s-disease 2025-05-21T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-supports-novel-endpoints-for-abli-therapeutics-risvodetinib-phase-3-trial-in-parkinson-s-disease 2025-05-21T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-leads-eur1-3-million-consortium-to-advance-mrna-therapeutics-using-lipid-nanoparticle-technology 2025-05-21T16:52:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-leads-eur1-3-million-consortium-to-advance-mrna-therapeutics-using-lipid-nanoparticle-technology 2025-05-21T16:52:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-warning-for-mrna-covid-19-vaccines-due-to-heart-side-effect-risk-in-young-males 2025-05-21T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-warning-for-mrna-covid-19-vaccines-due-to-heart-side-effect-risk-in-young-males 2025-05-21T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/waters-acquires-halo-labs-to-enhance-biologic-therapy-analysis-capabilities 2025-05-21T16:51:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-acquires-halo-labs-to-enhance-biologic-therapy-analysis-capabilities 2025-05-21T16:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-pharmaceuticals-secures-3-million-investment-to-advance-novel-age-reversal-drug-for-rare-diseases 2025-05-21T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-pharmaceuticals-secures-3-million-investment-to-advance-novel-age-reversal-drug-for-rare-diseases 2025-05-21T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-clinical-trial-shows-vagus-nerve-stimulation-significantly-improves-spinal-cord-injury-recovery 2025-05-21T16:50:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-clinical-trial-shows-vagus-nerve-stimulation-significantly-improves-spinal-cord-injury-recovery 2025-05-21T16:50:08+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-drug-pipeline-shows-promising-diversity-as-88-trials-recruit-patients-in-2025 2025-05-21T16:50:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-drug-pipeline-shows-promising-diversity-as-88-trials-recruit-patients-in-2025 2025-05-21T16:50:06+00:00 hourly 0.9 https://trial.medpath.com/news/reshape-lifesciences-announces-merger-with-vyome-and-asset-sale-to-biorad-amid-q1-2025-financial-results 2025-05-21T16:49:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reshape-lifesciences-announces-merger-with-vyome-and-asset-sale-to-biorad-amid-q1-2025-financial-results 2025-05-21T16:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/basil-systems-secures-11-5m-to-revolutionize-life-sciences-decision-making-with-ai 2025-05-21T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basil-systems-secures-11-5m-to-revolutionize-life-sciences-decision-making-with-ai 2025-05-21T16:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-kabi-launches-tyenne-r-canada-s-first-tocilizumab-biosimilar-for-autoimmune-conditions 2025-05-21T16:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-kabi-launches-tyenne-r-canada-s-first-tocilizumab-biosimilar-for-autoimmune-conditions 2025-05-21T16:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-efficacy-of-traditional-chinese-medicine-si-shen-wan-for-treating-ibs-d 2025-05-21T16:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-efficacy-of-traditional-chinese-medicine-si-shen-wan-for-treating-ibs-d 2025-05-21T16:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/mazindol-er-shows-promising-dual-action-against-fentanyl-addiction-in-preclinical-studies 2025-05-21T16:48:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mazindol-er-shows-promising-dual-action-against-fentanyl-addiction-in-preclinical-studies 2025-05-21T16:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/protagenic-therapeutics-secures-3-1-million-to-advance-cns-drug-pipeline-following-phytanix-bio-merger 2025-05-21T16:47:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagenic-therapeutics-secures-3-1-million-to-advance-cns-drug-pipeline-following-phytanix-bio-merger 2025-05-21T16:47:17+00:00 hourly 0.9 https://trial.medpath.com/news/biodlink-secures-brazil-gmp-certification-expanding-global-reach-for-bevacizumab-biosimilar 2025-05-21T16:46:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodlink-secures-brazil-gmp-certification-expanding-global-reach-for-bevacizumab-biosimilar 2025-05-21T16:46:46+00:00 hourly 0.9 https://trial.medpath.com/news/synfini-and-multispan-partner-to-accelerate-gpcr-drug-discovery-using-ai-and-automation 2025-05-21T16:46:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synfini-and-multispan-partner-to-accelerate-gpcr-drug-discovery-using-ai-and-automation 2025-05-21T16:46:40+00:00 hourly 0.9 https://trial.medpath.com/news/uni-bio-science-group-s-diquafosol-sodium-eye-drops-receives-nmpa-approval-for-dry-eye-syndrome-treatment-in-china 2025-05-21T16:46:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uni-bio-science-group-s-diquafosol-sodium-eye-drops-receives-nmpa-approval-for-dry-eye-syndrome-treatment-in-china 2025-05-21T16:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/ai-tools-show-promise-in-improving-her2-breast-cancer-classification-and-treatment-eligibility 2025-05-21T16:46:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-tools-show-promise-in-improving-her2-breast-cancer-classification-and-treatment-eligibility 2025-05-21T16:46:29+00:00 hourly 0.9 https://trial.medpath.com/news/biosergen-s-bsg005-shows-promise-against-resistant-fungal-infections-in-clinical-trial 2025-05-21T16:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosergen-s-bsg005-shows-promise-against-resistant-fungal-infections-in-clinical-trial 2025-05-21T16:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/tecentriq-and-avastin-combined-with-tace-shows-significant-benefit-in-unresectable-liver-cancer-trial 2025-05-21T16:12:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tecentriq-and-avastin-combined-with-tace-shows-significant-benefit-in-unresectable-liver-cancer-trial 2025-05-21T16:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-s-antiviral-phm23-selected-for-university-of-georgia-s-100m-bird-flu-challenge-submission 2025-05-21T16:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxytran-s-antiviral-phm23-selected-for-university-of-georgia-s-100m-bird-flu-challenge-submission 2025-05-21T16:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-launches-zemdri-plazomicin-in-india-to-combat-antimicrobial-resistance 2025-05-21T16:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-launches-zemdri-plazomicin-in-india-to-combat-antimicrobial-resistance 2025-05-21T16:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/new-global-report-reveals-comprehensive-landscape-of-chemotherapy-induced-diarrhea-clinical-trials 2025-05-21T16:10:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-global-report-reveals-comprehensive-landscape-of-chemotherapy-induced-diarrhea-clinical-trials 2025-05-21T16:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/worldwide-clinical-trials-joins-wcg-s-avoca-quality-consortium-to-enhance-clinical-trial-standards 2025-05-21T16:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/worldwide-clinical-trials-joins-wcg-s-avoca-quality-consortium-to-enhance-clinical-trial-standards 2025-05-21T16:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-organoids-and-crispr-technology-transform-cancer-research-and-precision-medicine 2025-05-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-derived-organoids-and-crispr-technology-transform-cancer-research-and-precision-medicine 2025-05-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-phase-2-oasis-trial-of-tnx-102-sl-for-acute-stress-reaction-following-trauma 2025-05-21T15:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-2-oasis-trial-of-tnx-102-sl-for-acute-stress-reaction-following-trauma 2025-05-21T15:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/upstream-bio-appoints-stacy-price-as-chief-technology-officer-to-advance-verekitug-development 2025-05-21T15:13:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upstream-bio-appoints-stacy-price-as-chief-technology-officer-to-advance-verekitug-development 2025-05-21T15:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/mallia-therapeutics-advances-novel-scd83-protein-treatment-for-hair-loss 2025-05-21T14:44:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mallia-therapeutics-advances-novel-scd83-protein-treatment-for-hair-loss 2025-05-21T14:44:07+00:00 hourly 0.9 https://trial.medpath.com/news/pace-life-sciences-passes-fda-pre-approval-inspection-strengthening-contract-manufacturing-capabilities 2025-05-21T14:15:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pace-life-sciences-passes-fda-pre-approval-inspection-strengthening-contract-manufacturing-capabilities 2025-05-21T14:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-plans-to-separate-diabetes-business-into-standalone-company 2025-05-21T13:44:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-plans-to-separate-diabetes-business-into-standalone-company 2025-05-21T13:44:18+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-appoints-ralph-hughes-as-chief-business-officer-to-advance-immunotherapy-pipeline 2025-05-21T13:44:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-pharmaceuticals-appoints-ralph-hughes-as-chief-business-officer-to-advance-immunotherapy-pipeline 2025-05-21T13:44:11+00:00 hourly 0.9 https://trial.medpath.com/news/clearflow-s-pleuraflow-system-reduces-cardiac-surgery-complications-by-41-in-large-clinical-trial 2025-05-21T13:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearflow-s-pleuraflow-system-reduces-cardiac-surgery-complications-by-41-in-large-clinical-trial 2025-05-21T13:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/triveni-bio-initiates-first-in-human-trial-of-triv-509-for-atopic-dermatitis-targeting-novel-kallikrein-pathway 2025-05-21T13:16:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triveni-bio-initiates-first-in-human-trial-of-triv-509-for-atopic-dermatitis-targeting-novel-kallikrein-pathway 2025-05-21T13:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/me-therapeutics-secures-140000-in-funding-to-advance-novel-mrna-cancer-therapies 2025-05-21T12:46:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/me-therapeutics-secures-140000-in-funding-to-advance-novel-mrna-cancer-therapies 2025-05-21T12:46:36+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-withdraws-fda-application-for-flu-covid-combo-vaccine-plans-resubmission-later-this-year 2025-05-21T12:44:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-withdraws-fda-application-for-flu-covid-combo-vaccine-plans-resubmission-later-this-year 2025-05-21T12:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/zura-bio-launches-phase-ii-tibushield-trial-for-novel-dual-inhibitor-in-hidradenitis-suppurativa 2025-05-21T12:43:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zura-bio-launches-phase-ii-tibushield-trial-for-novel-dual-inhibitor-in-hidradenitis-suppurativa 2025-05-21T12:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ind-clearance-for-immunoglobulin-eye-drops-to-treat-dry-eye-disease 2025-05-21T12:43:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ind-clearance-for-immunoglobulin-eye-drops-to-treat-dry-eye-disease 2025-05-21T12:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-s-oral-cholera-vaccine-hillchol-successfully-completes-phase-iii-trials 2025-05-21T12:43:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-biotech-s-oral-cholera-vaccine-hillchol-successfully-completes-phase-iii-trials 2025-05-21T12:43:20+00:00 hourly 0.9 https://trial.medpath.com/news/dementia-discovery-fund-secures-269m-in-second-fund-to-accelerate-novel-therapeutics-development 2025-05-21T12:43:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dementia-discovery-fund-secures-269m-in-second-fund-to-accelerate-novel-therapeutics-development 2025-05-21T12:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/obesity-drug-pipeline-surges-with-100-therapies-from-80-companies-in-2025 2025-05-21T12:43:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obesity-drug-pipeline-surges-with-100-therapies-from-80-companies-in-2025 2025-05-21T12:43:15+00:00 hourly 0.9 https://trial.medpath.com/news/juvenescence-secures-76m-in-series-b-1-funding-led-by-abu-dhabi-s-m42-for-age-related-disease-therapeutics 2025-05-21T12:42:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juvenescence-secures-76m-in-series-b-1-funding-led-by-abu-dhabi-s-m42-for-age-related-disease-therapeutics 2025-05-21T12:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-overturns-patent-rejection-for-taiho-pharmaceutical-s-anticancer-compound 2025-05-21T12:42:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-overturns-patent-rejection-for-taiho-pharmaceutical-s-anticancer-compound 2025-05-21T12:42:40+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-showcases-groundbreaking-cancer-research-at-asco-2025-with-two-plenary-presentations 2025-05-21T12:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-showcases-groundbreaking-cancer-research-at-asco-2025-with-two-plenary-presentations 2025-05-21T12:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/msd-expands-opevesostat-clinical-program-to-include-breast-endometrial-and-ovarian-cancers 2025-05-21T12:42:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-expands-opevesostat-clinical-program-to-include-breast-endometrial-and-ovarian-cancers 2025-05-21T12:42:29+00:00 hourly 0.9 https://trial.medpath.com/news/applied-stemcell-launches-hypoimmunogenic-hipsc-products-to-advance-allogeneic-cell-therapy-development 2025-05-21T12:42:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-stemcell-launches-hypoimmunogenic-hipsc-products-to-advance-allogeneic-cell-therapy-development 2025-05-21T12:42:23+00:00 hourly 0.9 https://trial.medpath.com/news/closed-loop-medicine-appoints-kate-woolland-as-ceo-to-drive-precision-dosing-commercialization 2025-05-21T12:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/closed-loop-medicine-appoints-kate-woolland-as-ceo-to-drive-precision-dosing-commercialization 2025-05-21T12:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/mirai-bio-partners-with-thermo-fisher-scientific-to-accelerate-genetic-medicine-development 2025-05-21T09:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirai-bio-partners-with-thermo-fisher-scientific-to-accelerate-genetic-medicine-development 2025-05-21T09:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-genetic-findings-challenge-traditional-understanding-of-coats-disease 2025-05-21T08:36:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-genetic-findings-challenge-traditional-understanding-of-coats-disease 2025-05-21T08:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-wins-patent-dispute-against-pfizer-over-pneumococcal-vaccine-components 2025-05-21T05:14:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-wins-patent-dispute-against-pfizer-over-pneumococcal-vaccine-components 2025-05-21T05:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/tubulis-and-bristol-myers-squibb-advance-first-collaborative-tubutecan-adc-into-clinical-trials 2025-05-21T05:14:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tubulis-and-bristol-myers-squibb-advance-first-collaborative-tubutecan-adc-into-clinical-trials 2025-05-21T05:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/kaida-biopharma-partners-with-northway-biotech-to-advance-novel-prolactin-receptor-antagonist-kad101-for-platinum-resistant-ovarian-cancer 2025-05-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaida-biopharma-partners-with-northway-biotech-to-advance-novel-prolactin-receptor-antagonist-kad101-for-platinum-resistant-ovarian-cancer 2025-05-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/accropeutics-oral-tyk2-jak1-inhibitor-shows-strong-efficacy-in-phase-2-psoriasis-trial 2025-05-21T04:44:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accropeutics-oral-tyk2-jak1-inhibitor-shows-strong-efficacy-in-phase-2-psoriasis-trial 2025-05-21T04:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/codex-labs-shaant-clearskin-probiotic-receives-us-patent-for-acne-treatment 2025-05-21T04:43:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/codex-labs-shaant-clearskin-probiotic-receives-us-patent-for-acne-treatment 2025-05-21T04:43:53+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-england-launches-world-first-gonorrhoea-vaccine-amid-record-infection-rates 2025-05-21T04:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-england-launches-world-first-gonorrhoea-vaccine-amid-record-infection-rates 2025-05-21T04:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-testing-emerges-as-critical-tool-in-brain-cancer-treatment-experts-emphasize 2025-05-21T03:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomic-testing-emerges-as-critical-tool-in-brain-cancer-treatment-experts-emphasize 2025-05-21T03:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/belimumab-shows-superior-efficacy-for-systemic-lupus-erythematosus-in-meta-analysis 2025-05-21T01:43:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belimumab-shows-superior-efficacy-for-systemic-lupus-erythematosus-in-meta-analysis 2025-05-21T01:43:05+00:00 hourly 0.9 https://trial.medpath.com/news/dupixent-demonstrates-superior-efficacy-over-xolair-in-first-head-to-head-respiratory-study 2025-05-21T01:43:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupixent-demonstrates-superior-efficacy-over-xolair-in-first-head-to-head-respiratory-study 2025-05-21T01:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-opposes-arbutus-s-request-to-reconsider-patent-case-limitations-in-covid-19-vaccine-dispute 2025-05-21T00:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-opposes-arbutus-s-request-to-reconsider-patent-case-limitations-in-covid-19-vaccine-dispute 2025-05-21T00:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-sues-hetero-labs-over-new-orilissa-patent-to-block-generic-endometriosis-drug 2025-05-21T00:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-sues-hetero-labs-over-new-orilissa-patent-to-block-generic-endometriosis-drug 2025-05-21T00:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-il-2-derivative-shows-complete-remission-in-advanced-skin-cancer-patient-after-one-year 2025-05-21T00:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-il-2-derivative-shows-complete-remission-in-advanced-skin-cancer-patient-after-one-year 2025-05-21T00:39:36+00:00 hourly 0.9